

Next generation sequencing in women affected by nonsyndromic premature ovarian failure displays new potential causative genes and mutations

Dora Janeth Fonseca, Ph.D.,^a Liliana Catherine Patiño, M.Sc.,^a Yohjana Carolina Suárez, M.Sc.,^a Asid de Jesús Rodríguez, M.Sc.,^a Heidi Eliana Mateus, M.D., M.Sc.,^a Karen Marcela Jiménez, M.Sc.,^a Oscar Ortega-Recalde, M.D., M.Sc.,^a Ivonne Díaz-Yamal, M.D.,^b and Paul Laissue, M.D., Ph.D.^a

^a Unidad de Genética, Grupo GENIUROS, Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario; and ^b Unidad de Fertilidad PMA, Clínica Marly, Bogota, Colombia

Objective: To identify new molecular actors involved in nonsyndromic premature ovarian failure (POF) etiology. **Design:** This is a retrospective case-control cohort study.

Setting: University research group and IVF medical center.

Patient(s): Twelve women affected by nonsyndromic POF. The control group included 176 women whose menopause had occurred after age 50 and had no antecedents regarding gynecological disease. A further 345 women from the same ethnic origin (general population group) were also recruited to assess allele frequency for potentially deleterious sequence variants.

Intervention(s): Next generation sequencing (NGS), Sanger sequencing, and bioinformatics analysis.

Main Outcome Measure(s): The complete coding regions of 70 candidate genes were massively sequenced, via NGS, in POF patients. Bioinformatics and genetics were used to confirm NGS results and to identify potential sequence variants related to the disease pathogenesis.

Result(s): We have identified mutations in two novel genes, *ADAMTS19* and *BMPR2*, that are potentially related to POF origin. *LHCGR* mutations, which might have contributed to the phenotype, were also detected.

Conclusion(s): We thus recommend NGS as a powerful tool for identifying new molecular actors in POF and for future diagnostic/prognostic purposes. (Fertil Steril® 2015;104:154–62. ©2015 by American Society for Reproductive Medicine.) **Key Words:** Premature ovarian failure, POF, next generation sequencing, *ADAMTS19*, *BMPR2*

回汤烧日 16月2日 19月1日 1月月1日

Use your smartphone to scan this QR code and connect to the discussion forum for this article now.*

Discuss: You can discuss this article with its authors and with other ASRM members at http:// fertstertforum.com/fonsecad-ngs-pof-potential-genes/

* Download a free QR code scanner by searching for "QR scanner" in your smartphone's app store or app marketplace.

Primary ovarian insufficiency is a heterogeneous pathology consisting of irregular ovulation secondary to distinct functional defects (1). This condition may evolve to premature ovarian failure (POF), a frequent condition characterized by the cessation of menses before age 40 and increased plasma gonadotropin levels (e.g., FSH >40 IU/L) (2). Women

Received February 28, 2015; revised April 7, 2015; accepted April 12, 2015; published online May 16, 2015.

D.J.F. has nothing to disclose. L.C.P. has nothing to disclose. Y.C.S. has nothing to disclose. A.d.J.R. has nothing to disclose. H.E.M. has nothing to disclose. K.M.J. has nothing to disclose. O.O.-R. has nothing to disclose. I.D.-Y. has nothing to disclose. P.L. has nothing to disclose. D.J.F. and L.C.P. should be considered similar in author order.

This study was supported by the Universidad del Rosario (grant no. CS/ABN062/Genetics 015).

Reprint requests: Professor Paul Laissue, M.D., Ph.D., Unidad de Genética, Grupo GENIUROS, Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, Colombia (E-mail: paul. laissue@urosario.edu.co).

Fertility and Sterility® Vol. 104, No. 1, July 2015 0015-0282/\$36.00 Copyright ©2015 American Society for Reproductive Medicine, Published by Elsevier Inc. http://dx.doi.org/10.1016/j.fertnstert.2015.04.016 with POF may have primary or secondary amenorrhea depending on whether the menarche has occurred (secondary) or not (primary) (3). Although most POF cases are considered idiopathic, distinct etiologies have been described, such as iatrogenic events, infectious agents, autoimmune conditions. environmental factors, and metabolic disorders. Most nonsyndromic POF cases that are considered idiopathic have pointed to the suspicion of a role for genetic and epigenetic etiological factors. Syndromic and nonsyndromic forms of POF have indeed been related to differing types of X chromosome and autosomal anomalies. For instance, it has been postulated that the hypergonadotropic hypogonadism observed in individuals with Turner's syndrome is due to the happloinsufficiency of genes located on the critical regions of the X chromosome that escape genetic inactivation (4). Fragile X syndrome has been associated with *FMR1* premutations and *FMR2* microdeletions (5). X chromosome deletions and translocations have led to identifying loci on the X chromosome (POF1-POF2 and POF3) that are related to the disease pathogenesis (6 and references therein).

Considerable efforts have been made during the last 20 years to identify sequence variants mainly located in POF coherent candidate genes' coding regions. However, less than 50 mutations have been validated in only nine genes (FSHR, LHCGR, NR5A1, NOBOX, FOXL2, FIGLA, BMP15, NANOS3, and STAG3) via functional assays as causative of nonsyndromic POF (7-20). Such apparent failure to identify POF's molecular origin has been partly due to the fact that very few family-related cases allow gene mapping by linkage analysis. In fact, POF etiological mutations are under strong negative selection because they participate in the molecular process responsible for reproductive fitness. Moreover, ovarian development and physiology imply fine-tuned quantitative molecular events that are regulated by hundreds of genes, thereby hampering the selection of coherent candidates for direct sequencing. It should be noted here that, although Sanger sequencing has been widely used for studying POF candidate gene-coding regions, it does suffer from technical limitations as it only allows up to \sim 700 base pairs (bp) to be analyzed per reaction. Studying large candidate genomic regions is therefore especially challenging since it involves numerous assays in setting up polymerase chain reaction (PCR) and sequencing experimental conditions. The next generation sequencing (NGS) approach (first used in 2007) has been widely used as an efficient alternative for detecting novel monogenic disease-related genes (21-23). This technique has been used more recently for studying, simultaneously, coding regions of thousands of genes (e.g., exome sequencing) that participate in the pathophysiology of multigene complex diseases (24-27).

The present study involved, for the first time, performing NGS assays on women affected by nonsyndromic POF. The complete coding regions of 70 candidate genes were sequenced in 12 women affected by POF. Bioinformatics and genetic analysis led to identifying mutations in *ADAMTS19* and *BMPR2* that are potentially related to POF origin. *LHCGR* mutations that might have contributed to the phenotype were also detected. NGS would thus seem to be a powerful tool for identifying new molecular actors involved in POF and for diagnostic/prognostic purposes.

MATERIALS AND METHODS Patients and Controls

Patients and controls were of Colombian origin. They were attending the Clínica Marly's PMA Fertility Unit (Bogotá, Colombia) and/or the Genetics Unit at the Universidad del Rosario (Bogotá, Colombia). Twelve POF-affected women (POF3, -4, -7, -9, -10, -11, -13, -17, -19, -23, and -136) were included in the present study. All had at least 6 months of amenorrhea before age 40, high FSH plasma levels (>40 IU/mL), and a normal 46,XX karyotype. Women having a background of anticancer treatment, pelvic surgery, ovarian infection, and/ or autoimmune disease were excluded from the study.

The control group (CG) included 176 women whose menopause had occurred after age 50 and had no antecedents regarding gynecological disease. These individuals reported having had regular menstrual cycles during their reproductive life spans and having had at least one child. A further 345 women (general population group [GP]; ages ranging from 19 to 63) from the same ethnic origin were also recruited to assess allele frequency for potentially deleterious alleles. Depending on availability, DNA samples were collected from family members of patients affected by potential pathogenic variants. These samples were used for studying candidate sequence variants potentially segregating with the phenotype. All of this study's clinical and experimental steps were approved by the Institutional Ethics Committee of both participating institutions. All individuals signed a written informed consent form.

NGS and Bioinformatics Analysis

Human genome sequences (Build Hg19) for the coding regions of the 70 genes of interest were retrieved from the UCSC Genome Browser (Table 1). These genes were selected after exploring public Internet databases, such as PubMed, Highwire, Geoprofiles, and MGI (Jackson Laboratory). For Internet exploration of the literature we included keywords, such as "genetics of sex determination," "genetics of folliculogenesis," "genetics of ovulation," "gene expression and ovary," "ovary and transcriptomics," "mouse models of premature ovarian failure," "premature ovarian failure," "premature ovarian failure genetics," and "primary ovarian insufficiency." In addition, we revised previous reports on gene sequencing involving women with POF to identify those displaying positive functional tests. The MGI database was use to specifically explore the POF phenotype. The Geoprofiles tool of the National Center for Biotechnology Information (NCBI) was used to evaluate expression patterns of selected genes.

Around 168,118 bases in length transcript sequences were flanked by 100 bp in the upstream and downstream regions, resulting in 247 kb target sequences. The 602 target coordinates were generated by merging the overlapping 706 exon coordinates in the selected genes' coding regions. These target sequences were masked for 3 kb length repeats, and a final set of 244 Kb sequences was considered for array design. Dense tiling of the target sequences was done to generate 60mer oligos regarding sense orientation. A final set of 241,399 probes was designed to fit into Agilent's 1X244K array, consisting of 241,399 experimental features and 2,105 control features. Total genomic DNA was isolated from leukocytes by use of the standard phenol/choloroform procedure. The DNA from the 12 POF samples was prepared and used for genome capture, as described elsewhere (28, 29). An Illumina GAII sequencer was used for high-throughput sequencing. The human

TABLE 1

Genes included in the sequencing microarray.

EKSG0000154734 ADAMTS1 A disintegrin and metalloprotenase with thrombospondin motifs 1 precusor EKSG0000125378 BMM4 Bore morphogenetic protein 4 precusor EKSG0000125378 BMM5 Bore morphogenetic protein 5 precusor EKSG0000113162 BMM5 Bore morphogenetic protein 5 precusor EKSG0000113164 BMM5 Bore morphogenetic protein 7 precusor EKSG0000113165 BMM7 Bore morphogenetic protein receit program EKSG00000113266 BMM71 Bore morphogenetic protein receit program EKSG0000011276 CDKN1B Cyclin-dependent kinase inhibitor 18 EKSG00000112766 CVP1941 Cyclon-dependent kinase inhibitor 18 EKSG00000112766 CVP141 Foldad box protein 02 EKSG0000011283 FMR1 Fraglita dox protein 02 EKSG00000112840 FMR1 Fraglita do	Ensembl ID	Gene name	Description
ENSCODD0145808 ADAMTS19 A disintegrin and metalloprotein as with thromboopnoin motifs 1 ⁶ precursor ENSCODD0112175 BMP5 Bore morphogenetic protein 5 precursor ENSCODD0112175 BMP5 Bore morphogenetic protein 5 precursor ENSCODD0112144 BMP5 Bore morphogenetic protein 5 precursor ENSCODD0112147 BMP6 Bore morphogenetic protein 5 precursor ENSCODD011276 CDKN18 C yee ENSCODD0112776 CDKN18 C yee ENSCODD0112776 CDKN18 E graph receptor ENSCODD0112776 CDKN18 E graph receptor ENSCODD0112776 CDKN18 E graph receptor ENSCODD0112776 CDKN18 E graph receptor test ENSCODD0112781 E GGA E graph receptor ENSCODD0112781 CGA E graph receptor E	ENSG00000154734	ADAMTS1	A disintegrin and metalloproteinase with thrombospondin motifs 1 precursor
ENSCO000125378 BMM4 Bore morphogenetic protein 4 precusor ENSCO000113175 BMM5 Bore morphogenetic protein 5 precusor ENSCO000113184 BMM7 Bore morphogenetic protein 5 precusor ENSCO000113085 BMM71 Bore morphogenetic protein 7 precusor ENSCO000113085 BMM71 Bore morphogenetic protein receptor type 15 precusor ENSCO0000113085 BMM71 Bore morphogenetic protein receptor type 15 precusor ENSCO000011257 CDVN1B Cyclin-dependent knase inhibitor 11 precusor ENSCO000017866 CVP19A1 Cyclin-dependent knase inhibitor 11 precusor ENSCO000017866 CVP19A1 Cyclin-dependent knase inhibitor 12 precusor ENSCO000017866 CVP19A1 Cyclin-dependent knase inhibitor 13 precusor ENSCO0000178733 FGL4 Fador in the germline alpha ENSCO000017888 FOROR Folkhead box protein C4 ENSCO000017888 FOROR Folkhead box protein C4 ENSCO000017888 FSFR Folkhead box protein C4 ENSCO000017888 FSFR Folkhead box protein C4 ENSCO000017888 FSFR Folkhead box protein C4	ENSG00000145808	ADAMTS19	A disintegrin and metalloproteinase with thrombospondin motifs 19 precursor
ENSCO200112175 BMP5 Bore morphogenetic protein 5 precursor ENSCO2000151144 BMP7 Bore morphogenetic protein 5 precursor ENSCO200013836 BMP15 Bore morphogenetic protein 7 precursor ENSCO200013836 BMP17 Bore morphogenetic protein receptor type 18 precursor ENSCO200013836 BMP17 Bore morphogenetic protein receptor type 2 precursor ENSCO2000112124 C/PDD2 Cplin Sequenci times inhibitor 18 ENSCO200011224 C/PDD2 Cplin Sequenci times inhibitor 18 ENSCO200011226 DMC1 Heinit recordination protein DMC /LILM 15 homolog ENSCO2000112376 CVP1 9A 1 Farage receptor ENSCO2000112370 FOXL2 Forhaad box protein 02 ENSCO2000114481 FOXD2 Forhaad box protein 02 ENSCO2000114481 FO	ENSG00000125378	BMP4	Bone morphogenetic protein 4 precursor
EMSG0000113462 BMM6 Bone morphogenetic proteins EMSG000011344 BMM7 Bone morphogenetic protein T precursor EMSG0000013485 BMM715 Bone morphogenetic protein receptor type-18 precursor EMSG0000013486 BMM718 Bone morphogenetic protein receptor type-18 precursor EMSG0000013486 CMP194 Chrophogenetic protein receptor type-18 precursor EMSG00000137669 CVP1941 Cytophomechic protein morphogenetic protein morphogenetic protein EMSG00000137669 CVP1941 Cytophomechic protein morphogenetic protein EMSG00000137669 CVP1941 Estrogen receptor testa EMSG00000137769 FAR1 Factor in the germine apha EMSG0000013777 FOX04 Forthead box protein EMSG0000137780 FAR1 Factor in the germine apha EMSG000013783 FGLA Factor in the germine apha EMSG0000013783 FGLA Factor in the ge	ENSG00000112175	BMP5	Bone morphogenetic protein 5 precursor
ENSCO00011144 BMP7 Bone morphogenetic protein 15 precursor ENSCO000130856 BMP15 Bone morphogenetic protein in ceceptor type-1 precursor ENSCO000111276 CDN/HB Cyclin dependent kinase inhibitor 18 ENSCO000111276 CDN/HB Cyclin dependent kinase inhibitor 18 ENSCO0001112769 CVP10A1 Cyclin dependent kinase inhibitor 18 ENSCO000102060 DAC1 Medic recombination protein DMC1/LIM15 homolog ENSCO0000173769 CVP10A1 Factor in the germine alpha ENSCO00001831 FSR1 Estrogen receptor beta ENSCO000018333 FACIA Factor in the germine alpha ENSCO000018370 FOXO3 Forthead box protein 03 ENSCO000018383 FOXO3 Forthead box protein 04 ENSCO000018481 FOXO3 Forthead box protein 04 ENSCO000013403 FSF Folistain precursor ENSCO000013403 FSF Folistain precursor ENSCO000014404 FZD4 Frizzele-4 precursor ENSCO0000174504 FZD4 Frizzele-4 precursor ENSCO0000174503 GA/H Gap junction alpha-4 protel	ENSG00000153162	BMP6	Bone morphogenetic protein 6 precursor
ENSCO000130385 BMPF15 Bone morphogenetic protein receptor type-18 precursor ENSCO0000138966 BMMPR18 Bone morphogenetic protein receptor type-18 precursor ENSCO0000141776 CDKN18 Cyph300-interacting transactivator 2 ENSCO000013841 CTED2 Cbp/300-interacting transactivator 2 ENSCO0000118766 CYP13A1 Cyptoneme P450 19A1 ENSCO0000118766 DEV1 Forgen receptor beta ENSCO0000118770 FOXA2 Forthead box protein 03 ENSCO0000118859 FOXA3 Forthead box protein 03 ENSCO0000118869 FOXA2 Forthead box protein 03 ENSCO0000118869 FOXA2 Forthead box protein 03 ENSCO0000118869 FOXA3 Forthead box protein 03 ENSCO0000118869 FOXA2 Forthead box protein 03 ENSCO0000118869 FOXA4 Forthead box protein 03 ENSCO000017820 FSPR Folicle-strunulating hormone neceptor precusor ENSCO000017820 FSPR Folicle-strunulating hormone neceptor precusor ENSCO000017820 FSPR Folicle-strunulating hormone neceptor precusor ENSCO000017820	ENSG00000101144	BMP7	Bone morphogenetic protein 7 precursor
ENSC0000138696 BMRP18 Bone morphogenetic protein incerptor type-1 precursor ENSC0000024217 BMRP2 Bone morphogenetic protein incerptor type-1 precursor ENSC00000114242 CURED2 Cbp/300-Interacting transactivetor 2 ENSC00000127869 CYPEDA1 Cytochrome P450 19A1 ENSC0000012870 EST Estrogen receptor tests ENSC0000012871 FRKA Estrogen receptor tests ENSC0000012870 FRKA Fragle X moral recardation 1 protein ENSC00000128870 FRKA Fragle X moral recardation 1 protein ENSC0000013889 FXX3 Fracthead box protein 03 ENSC0000013889 FXX3 Fracthead box protein 04 ENSC0000013889 FXX8 Folltwale barp recursor ENSC0000013889 FXX8 Folltwale barp recursor ENSC0000013889 FXX8 Folltwale barp recursor ENSC0000013840 FZPA Folltwale barecursor	ENSG00000130385	BMP15	Bone morphogenetic protein 15 precursor
ENSG000011276 BMR2 Bone morphogenetic protein receptor type-2 precursor ENSG0000011276 CDKN18 Cypin300-interacting transactivator 2 ENSG0000011276 CMP19A1 Cypin300-interacting transactivator 2 ENSG0000010206 DMC1 Meabure recombination protein DMC1/LIM15 homolog ENSG0000137386 CYP19A1 Fraction the gerraline alpha ENSG0000013737 FRA Fraction the gerraline alpha ENSG00000138770 FOX22 Forkhead box protein 03 ENSG0000013889 FOX33 Forkhead box protein 03 ENSG0000017880 FSHR Follicle-stimulating hormone receptor precursor ENSG0000017820 FSHR Follicle-stimulating hormone receptor precursor ENSG0000017821 GMA4 Gap incicion alpha-4 protein ENSG00000178261 GMHR Fonladoropm-releasing hormone receptor ENSG00000178263 GMHR Gonadoropm-relea	ENSG00000138696	BMPR1B	Bone morphogenetic protein receptor type-1B precursor
ENSCODUDITI276 CDX/IVB Cyclin-dependent knase inhibitor 18 ENSCODUDITABLE CTED2 C/p/p300-intracting transactivator 2 ENSCODUDITABLE CTED2 C/p/p300-intracting transactivator 2 ENSCODUDITABLE ESTI Estrogen receptor ENSCODUDITABLE ESTI Estrogen receptor ENSCODUDITABLE ESTI Estrogen receptor ENSCODUDITABLE FMRI Fragile X mental relarkation 1 protein ENSCODUDITABLE FOMRI Fragile X mental relarkation 1 protein ENSCODUDITABLE FORME Folkead box protein 03 ENSCODUDITABLE FORME Folkead box protein 04 ENSCODUDITABLE FSFR Follitorijn subunit beta precursor ENSCODUDITABLE FSFR Follitable-stimulating hormone receptor precursor ENSCODUDITABLE GAM Grap junction alpha-4 protein ENSCODUDITABLE GAM Grap junction alpha-4 protein ENSCODUDITABLE GAM+A GonadotTopin-releasing hormone receptor ENSCODUDITABLE GAM+A GonadotTopin-releasing hormone receptor ENSCODUDITABLE GAM+A Gonadot	ENSG00000204217	BMPR2	Bone morphogenetic protein receptor type-2 precursor
ENSCOUDD0164442 CTED2 C bp/p300-nteracting transactivator 2 ENSCOUDD0173669 DMC1 Meotic recombination protein DMC1/LIM15 homolog ENSCOUDD01737669 DMC1 Meotic recombination protein DMC1/LIM15 homolog ENSCOUDD0173769 ESR1 Estrogen receptor beta ENSCOUDD017373 FRGLA Factor in the germine alpha ENSCOUDD017373 FRGLA Factor in the germine alpha ENSCOUDD017373 FRGLA Factor in the germine alpha ENSCOUDD0174804 FRGLA Factor in the germine alpha ENSCOUDD0174804 FOXG3 Forkhead box protein 03 ENSCOUDD0174804 FOXG4 Forkhead box protein 04 ENSCOUDD0174804 F2D4 Frizle4-4 precursor ENSCOUDD017561 GLA1 Gap junction alpha-4 protein ENSCOUDD0174804 F2D4 Frizle4-4 precursor ENSCOUDD0174817513 GLA4 Gap junction alpha-4 protein ENSCOUDD01748174 FORMH1 Progenadolberin-1 precursor ENSCOUDD0174817513 GLA4 Gap iunction alpha-4	ENSG00000111276	CDKN1B	Cyclin-dependent kinase inhibitor 1B
ENSCOUDUNID 378b9 CPP 901 CytOchrone P301 19A1 ENSCOUDUNID 20050 DMC1 Medice recombination protein DMC1/LIM15 homolog ENSCOUDUNID 20050 EST2 Estrogen receptor bata ENSCOUDUNID 20051 FGLA Factor in the germline alpha ENSCOUDUNID 20051 FMR1 Fragile X mental recreation to the germline alpha ENSCOUDUNID 20051 FORMA Forthead box protein C3 ENSCOUDUNID 20051 FORMA Forthead box protein C4 ENSCOUDUNID 20051 FORMA Forthead box protein C3 ENSCOUDUNID 200561 FORMA Forthead box protein C4 ENSCOUDUNID 2005661 GUA1 Gap junction alpha-4 protein ENSCOUDUNID 20057561 GUA1 Gap junction alpha-4 protein ENSCOUDUNID 2005761 GUA4 Gap junction alpha-4 protein ENSCOUDUNID	ENSG00000164442	CITED2	Cbp/p300-interacting transactivator 2
Encoduction Divit / Method: Reconstruction Encoduction Divit / Method: Reconstruction ENSCODUCTION ESR1 Estrogen ENSCODUCTION Estrogen receptor ENSCODUCTION Estrogen receptor ENSCODUCTION Estrogen receptor ENSCODUCTION Estrogen receptor ENSCODUCTION Forkinad box protein ENSCOD	ENSG00000137869	CYPI9AI	Cytochrome P450 19A1
Ensition/000031631 ES/1 Estrogen receptor beta ENSGOD00118731 FRGA Estrogen receptor beta ENSGOD00118781 FRGA Estrogen receptor precursor ENSGOD00011888 FSH Folitastin precursor ENSGOD00017820 FSH Folitastin precursor ENSGOD00017820 FSH Folitastin precursor ENSGOD00017820 GAA Gap junction alpha-1 protein ENSGOD00017820 GAA Gap junction alpha-1 protein ENSGOD00017821 GAA Gap junction alpha-1 protein ENSGOD00017821 GAA Gap junction alpha-1 proteins ENSGOD000172399 INHA Inhibin beta A chain precursor ENSGOD000172391 INHB Inhibin beta A chain precursor ENSGOD000172818 INHBA Inhibin beta C schain precursor ENSGOD000172818 INHBA Inhibin beta C schain precursor ENSGOD000172818 <	ENSG00000100206		Estragen recenter
Link200001140039 Link2 Lanught lettprofile Link200001120381 HMR1 Fragile Xmental retardation 1 protein ENSG00001120381 HMR1 Fragile Xmental retardation 1 protein ENSG00001120381 HMR1 Froithead box protein D3 ENSG00001120381 FMR Folithead box protein 03 ENSG00000134281 FXH Folithead box protein 03 ENSG00000134281 FXH Folithead box protein 03 ENSG00000134363 FXH Folithead box protein 03 ENSG00000134363 FXH Folithead box protein 03 ENSG00000134363 FXH Folithead box protein 14 ENSG00000134363 GAI Gap junction alpha-4 protein ENSG0000015401 GAI Gap junction alpha-4 protein ENSG0000015403 GAHH Prograndatiberin-1 procursor ENSG0000015403 GAHH Foradotropin-releasing formone receptor ENSG00000153083 INHB Inhibib heta A chain precursor ENSG0000015404 KTT Mastyterm cell	ENSG0000091851		Estrogen receptor beta
ENSG000012081 F/R/T Fragile Xmental relardation 1 protein ENSG0000118689 F/X/G3 Forkhead box protein 0.3 ENSG0000118689 F/X/G3 Forkhead box protein 0.4 ENSG0000118689 F/X/G4 Forkhead box protein 0.4 ENSG0000118689 F/X/G4 Forkhead box protein 0.4 ENSG000011889 F/X/G4 Forkhead box protein 0.4 ENSG000017859 F/X/G4 Forkhead box protein 1.2 ENSG000017859 F/X/G4 Forkhead box protein ENSG000017859 F/X/G4 Forkhead box protein ENSG000017859 F/X/G4 Forkhead box protein ENSG0000017859 F/X/G4 Forkhead box protein ENSG0000017859 F/X/G4 Forkhead box protein ENSG0000017858 F/X/G4 Forkhead box protein 1.2 ENSG0000017867 E/EPR Leptin receivsor ENSG0000017867 E/EPR Leptin receivsor ENSG000001867 E/EPR Leptin receivsor ENSG0000016678 E/EPR Leptin receivsor ENSG0000016678 E/EPR Leptin receivsor ENSG0000016678 E/EPR Leptin receivsor ENSG0000017855 F/X/A K/IZ ENSG0000017855 F/X	ENSG00000140009	FIGLA	Eactor in the germline alpha
ENSG00001183770 FXXL2 Forkhead box protein 0.2 ENSG0000118689 FXHG Forkhead box protein 0.3 ENSG0000118689 FXHG Forkhead box protein 0.4 ENSG0000118808 FXHF Folicle-stimulating hormone receptor precursor ENSG0000138383 FXT Folicitatin precursor ENSG0000138383 FXT Folicitatin precursor ENSG0000138383 FXT Folicitatin precursor ENSG0000138383 FXT Folicitatin protein ENSG0000154004 FZD4 Fritzle4 precursor ENSG0000154004 GDF9 Growthd/ffreetriation factor 9 precursor ENSG000015401 GA/1 Gap junction alpha-1 protein ENSG000015183 G/A4 Gap junction alpha-1 protein ENSG0000118383 INHA Inhibin Eat A chain precursor ENSG000015183 G/AH Gap junction alpha-1 protein ENSG0000015183 G/AH Gap junction alpha-1 protein ENSG0000015183 INHA Inhibin beta A chain precursor ENSG0000015183 INHA Inhibin beta A chain precursor ENSG0000015188 INHA Inhibin beta A chain precursor ENSG0000015188 INHB Inhibin beta C chain precursor ENSG0000015180 INHB EXIST IN EXIST IN EXIST Precursor ENSG0000015104 KTT Mastriem cell growth factor receptor precursor ENSG00000116014 KTST K KISS-1 precursor ENSG00000116014 KTT Mastriem cell growth factor receptor precursor ENSG00000116014 KTT Mastriem cell growth factor receptor precursor ENSG000000116788 LEPR Leptin treceptor precursor ENSG0000001826 LHB Lutropin subunit beta precursor ENSG0000001826 LHB Lutropin subunit beta precursor ENSG00000017487 NA/25 NACHT, LIRI and PYD domains-containing protein 5 ENSG00000017487 NA/25 NACHT, LIRI and PYD domains-containing protein 5 ENSG0000017487 NA/25 NACHT, LIRI and PYD domains-containing protein 5 ENSG00000017487 NA/25 NACHT, HR and PYD domains-containing protein 5 ENSG00000017487 FAR NA/25 NACHT, HR and PYD domains-containing protein 5 ENSG00000017487 POR Product precursor ENSG00000017487 POR Product precursor ENSG00000017487 POR Product precursor ENSG00000017484 PRIR Product precursor ENSG00000017585 FAR/ACT Meno	ENSG00000102081	FMR1	Fracile X mental retardation 1 protein
ENSEG0000118689 FDX03 Forkhead box protein O3 ENSEG0000131808 FSHB Forkhead box protein O4 ENSEG0000131808 FSHB Forkhead box protein O4 ENSEG000017820 FSHR Forkhead box protein O4 ENSEG000017820 FSHR Forkhead box protein O4 ENSEG000017820 FSHR Forkhead box protein O4 ENSEG0000174804 FZD4 Frizzlet4 precursor ENSEG0000152661 G1A1 Gap junction alpha+ protein ENSEG000012561 G1A1 Gap junction alpha+ protein ENSEG000012561 G1A1 Gap junction alpha+ protein ENSEG0000122661 WHA Gongoardolberin-1 precursor ENSEG0000122661 WHA Gongoardolberin-1 precursor ENSEG0000122661 WHA Inhibin alpha chain precursor ENSEG0000122661 WHA Inhibin alpha Chain precursor ENSEG0000122661 WHA Inhibin bats A chain precursor ENSEG0000175188 WHA Inhibin bats A chain precursor ENSEG0000175188 WHA Inhibin bats Chain precursor ENSEG0000175188 WHA EX551 Receptor ENSEG0000175188 WHBC Inhibin bats Chain precursor ENSEG0000175188 WHBC Ex551 Precursor ENSEG0000175188 WHBC Ex551 Precursor ENSEG0000175184 KITT Mastisten cell growth factor receptor precursor ENSEG0000115140 KITT Mastisten cell growth factor receptor precursor ENSEG000011614 KIS51 Recursor ENSEG000011614 KITS LEPR Leutropin-shoridg-0 adotropic hormone receptor precursor ENSEG000011678 EFPR Leutropin-shoridg-0 adotropic hormone receptor precursor ENSEG000001826 LHBB Lutropin shoridg-0 formone receptor precursor ENSEG000016264 LHB Extra Multis protein hormolog 4 ENSEG0000017488 MSH4 Multis protein hormolog 5 ENSEG000017487 NAU25 NACHT, LRR and P7D domains-containing protein 5 ENSEG00000174875 WANOS2 Nanos hormolog 3 ENSEG0000017487 PRCA ENSEG00000174875 WANOS2 Nanos hormolog 3 ENSEG0000017448 PR PR Projection receptor (PR) ENSEG000001744 PRA ENSEG000001744	ENSG00000183770	FOXI 2	Forkhead box protein L2
ENSG0000184481 FOXO4 Forthead box protein O4 ENSG000017820 F5HR Follitopin subunit beta precursor ENSG000017820 F5HR Follitopin subunit beta precursor ENSG0000178404 F2D4 Friziel-4 precursor ENSG0000174804 F2D4 Friziel-4 precursor ENSG0000174804 F2D4 Friziel-4 precursor ENSG0000174804 F2D4 Friziel-4 precursor ENSG0000018751 G1A4 Gap junction alpha-4 protein ENSG0000018751 G1A4 Gap junction alpha-4 protein ENSG0000018751 G1A4 Gap junction alpha-4 protein ENSG0000018763 G1NHR Gonadotropin-releasing hormone receptor ENSG0000012863 INHAB Inhibin bate A chain precursor ENSG00000175188 INHBE Inhibin bate B chain precursor ENSG00000175188 INHBE Inhibin bate B chain precursor ENSG0000017448 K2S1 Metastase suppresor K1S2 precursor ENSG0000016744 KISS1R K1S51 receptor ENSG0000017448 KISS1R K1S51 receptor ENSG0000017448 KISS1R K1S51 receptor precursor ENSG0000017444 KIT MastVstem Cell growth factor receptor precursor ENSG0000017404 KIT MastVstem Cell growth factor receptor precursor ENSG0000017404 KIT MastVstem Cell growth factor receptor precursor ENSG0000016784 LHB Lutropin subunit beta precursor ENSG0000016784 LHB Lutropin subunit beta precursor ENSG0000016785 LHB Lutropin subunit beta precursor ENSG0000016786 K1H8 MUS protein homolog 4 ENSG0000017487 NAUS5 NACHT, IR and PVD domains-containing protein 5 ENSG0000018425 NANOS2 Nanos homolog 3 ENSG0000018425 NANOS3 Nanos homolog 3 ENSG0000018425 NANOS3 Nanos homolog 3 ENSG0000018425 PGR Progesterone receptor (PR) ENSG0000018426 PGR NAUS57 NANOS3 Nanos homolog 3 ENSG0000018425 PGR PGR Progesterone receptor (PR) ENSG0000018425 PGR PGR Progesterone receptor (PR) ENSG0000018425 PGR PGR Progesterone receptor (PR) ENSG000001744 PGR NAUS57 PGR Prodecimaes ENSG000001744 PGR PGR Prodecimaes ENSG0000001744 PGR PGR Prodecimaes ENSG000001744 PGR PGR PGR Prodecimaes ENSG000001744 PGR PGR Prodecimaes ENSG000001755 PGR PGR2 Prostaglandin E, r	ENSG00000118689	FOXO3	Forkhead box protein Q3
ENSG0000131808 F5HB Follidestimulating hormone receptor precursor ENSG0000179820 F5H Folicidestimulating hormone receptor precursor ENSG0000174804 FZD4 Frizzled-4 precursor ENSG0000174804 GD9 Growth/differentiation factor 9 precursor ENSG000017513 GIA4 Gap junction alpha-1 protein ENSG0000187513 GIA4 Gap junction alpha-1 protein ENSG0000187513 GIA4 Gap junction alpha-1 protein ENSG00000187513 GINHR Gonadotropin-releasing hormone receptor ENSG0000016163 GINHR Gonadotropin-releasing hormone receptor ENSG0000015281 INHBA Inhibin bata C-hain precursor ENSG0000015188 INHRC Inhibin bata C-hain precursor ENSG0000015184 KTS1 Metastasis-suppressor KIS5-1 precursor ENSG00000157404 KTT Mastasis-suppressor KIS5-1 precursor ENSG00000161678 LEPR Leptoin receptor precursor ENSG0000016224 LHR Lutropin-suburit bata precursor ENSG0000017482 KFI Multi protein homolog 5 ENSG0000017482 LHPR Lutropin-suburit bata precursor ENSG0000017482 LHR Lutropin-suburit bata precursor ENSG0000017482 LHR Lutropin-suburit bata	ENSG0000184481	FOXO4	Forkhead box protein O4
ENSG0000170820F5/HRFollicistimulating hormone receptor precursorENSG0000174804F2D4Frizzlet-4 precursorENSG0000152661G/A1Gap junction alpha-1 proteinENSG0000174804G/D9Growth/differentiation factor 9 precursorENSG0000174804G/A1Gap junction alpha-1 proteinENSG0000174804G/A1Gap junction alpha-1 proteinENSG0000174737G/R/HRGonadotopin-releasing hormone receptorENSG0000123999IN/HAInhibin alpha chain precursorENSG0000122641IN/HBAInhibin beta A chain precursorENSG000001275189IN/HBAInhibin beta A chain precursorENSG0000016014KJSS1Metatasis-suppresor KJSS-1 precursorENSG00000167340K/TMassis-suppresor KJSS-1 precursorENSG0000017420NARALutropin suburit beta precursorENSG0000017420NSH5MutS protein homolog 5ENSG0000017420NANS4MutS protein homolog 5ENSG0000017440MSH5NACHT, LRR and	ENSG00000131808	FSHB	Follitropin subunit beta precursor
ENSG0000134363 F5T F0IIstatin precursor ENSG0000164404 GDP Growth/differentiation factor 9 precursor ENSG0000137513 GJA4 Gap junction alpha-1 protein ENSG0000137513 GJA4 Gap junction alpha-1 protein ENSG0000137513 GJA4 Gap junction alpha-1 protein ENSG0000137437 GJRH1 Progonadoliberin-1 precursor ENSG000012399 JNHA Inhibin alpha chain precursor ENSG000012399 JNHA Inhibin alpha chain precursor ENSG000012363 JNHBA Inhibin beta A chain precursor ENSG0000173189 JNHA Inhibin beta A chain precursor ENSG0000173189 JNHBA Inhibin beta C chain precursor ENSG0000173189 JNHBC Inhibin beta C chain precursor ENSG000017498 KISS1 Metastasi-suppressor KISS-1 precursor ENSG000017498 KISS1 Metastasi-suppressor KISS-1 precursor ENSG00000157404 KIT Mastytem cell growth factor receptor precursor ENSG00000157404 KIT Mastytem cell growth factor receptor precursor ENSG0000016778 LEPR Leptin receptor precursor ENSG0000018262 LHB Lutropin-choriogonadotropic hormone receptor precursor ENSG0000018262 LHB Lutropin-choriogonadotropic hormone receptor precursor ENSG0000018262 NANDS2 NANDS2 NANDS2 NANDS2 NANDS2 NANDS2 NANDS2 ENSG000001825 NANDS2 NANDS2 NANDS2 NANDS2 NANDS2 ENSG000001825 NANDS2 NANDS2 NANDS2 NANDS2 NANDS2 NANDS2 ENSG000001825 NANDS2 NANDS2 NANDS2 NANDS4 ENSG000001825 NANDS2 NANDS2 NANDS2 NANDS HOMOLOG 3 ENSG000001825 NANDS2 NANDS2 NANDS2 NANDS HOMOLOG 3 ENSG000001825 NANDS2 NANDS HOMOLOG 3 ENSG000001825 PGRMC1 Metaster and PTO domains-containing protein 5 ENSG000001825 PGRMC1 Metaster and PTO domains-containing protein 5 ENSG000001825 PGRMC1 Metaster and PTO domains-containing protein 1 ENSG000001825 PGRMC1 Metaster and PTO domains-containing interin 1 ENSG000001825 PGRMC1 Metaster and protein factor 1 ENSG0000018264 POR NDEDX, HURAN Isoform 2 ENSG0000017355 PGR Prostaglandin GH synthase 2 precursor ENSG0000017355 PGRMC1 Metaster anscription factor 1 ENSG0000017355 PGRMC1 Metaster precursor ENSG000	ENSG00000170820	FSHR	Follicle-stimulating hormone receptor precursor
ENSG0000174804 Fiz2d-4 precursor ENSG0000152661 G/A1 Gap junction alpha-4 protein ENSG0000152661 G/A1 Gap junction alpha-4 protein ENSG0000127513 G/A4 Gap junction alpha-4 protein ENSG0000127437 G/R/H1 Progonadoliberin-1 precursor ENSG0000123999 IN/HA Inhibin alpha chain precursor ENSG0000123999 IN/HA Inhibin alpha chain precursor ENSG0000123999 IN/HA Inhibin beta 8 chain precursor ENSG000012589 IN/HB Inhibin beta 8 chain precursor ENSG000012589 IN/HB Inhibin beta 8 chain precursor ENSG0000163083 IN/HBB Inhibin beta 8 chain precursor ENSG0000161614 K/SS1 R K/SS1 Precursor ENSG00001657404 K/T Mastter ell growth factor receptor precursor ENSG0000014626 L/HB Lutropin subunit beta precursor ENSG0000016678 LEPR Leptin receptor precursor ENSG0000016678 LLPR Leptin receptor precursor ENSG0000016678 M/HA MUTS protein homolog 5 ENSG0000016624 L/H/S Lutropin-choriogonad/tropic homone receptor precursor ENSG0000016264 L/HS Lutropin subunit beta precursor ENSG0000016264 L/H/S Lutropin subunit beta Precursor ENSG0000016264 L/H/S NACHT, LRR and PVD domains-containing protein 5 ENSG0000016264 L/H/S NACHT, LRR and PVD domains-containing protein 5 ENSG0000016825 NAN/OS2 Nanos homolog 3 ENSG00000168425 NAN/OS2 Nanos homolog 3 ENSG0000016410 NOBOX NOBOX, NOBOX, HUMAN koform 2 ENSG0000016410 NOBOX NOBOX NOBOX, HUMAN koform 2 ENSG0000016410 NOBOX NOBOX, HUMAN koform 2 ENSG0000016459 PGR/MC1 Membrane-associated progesterone receptor component.1 ENSG000001744 NTF4 NuEPS Prosterin receptor (FR) ENSG0000017355 PGR/MC1 Membrane-associated progesterone receptor component.1 ENSG0000017355 PGS2 Prostajandin jr, receptor FP2 subtype ENSG0000017355 PGS2 Prost	ENSG00000134363	FST	Follistatin precursor
ENSG0000154404 GDP9 Growth/differentiation factor 9 precursor ENSG0000187513 GJA Gap junction alpha-4 protein ENSG000019753 GJA GJA Gap junction alpha-4 protein ENSG000019753 GJA GJA Gap junction alpha-4 protein ENSG000019753 GJA GJA GAP GOD GJA	ENSG00000174804	FZD4	Frizzled-4 precursor
ENSG0000152661 G/A Gap junction alpha-4 protein ENSG0000147437 G/R/H Progonadoliberin-1 precursor ENSG0000137939 //HA Inhibin alpha chain precursor ENSG000013399 //HA Inhibin alpha chain precursor ENSG000013399 //HA Inhibin beta A chain precursor ENSG0000136083 //HBB Inhibin beta A chain precursor ENSG0000175189 //HBC Inhibin beta A chain precursor ENSG0000170498 K/SS1 Metaslas-suppressor KIS5-1 precursor ENSG0000161014 K/SS1R K/SS-1 receptor ENSG0000161614 K/SS1R K/SS-1 receptor ENSG00001616744 K/IT Mastis-suppressor KIS5-1 precursor ENSG000016826 //HB LetPR Letpin receptor precursor ENSG000016426 //HB LetPR Letpin subunit beta precursor ENSG000016426 //HB N/HS M/HS M/HS M/HS M/HS M/HS M/HS M/HS M	ENSG00000164404	GDF9	Growth/differentiation factor 9 precursor
ENSG0000137513 G/A Gap Lunction alpha-4 protein ENSG000019163 G/NRH1 Progonadoliberin-1 precursor ENSG00001232999 ///HA Inbibin beta A chain precursor ENSG0000122641 ///HBA Inbibin beta A chain precursor ENSG0000175189 ///HBA Inbibin beta A chain precursor ENSG0000175189 ///HBC Inbibin beta C chain precursor ENSG0000175189 ///HBC Inbibin beta C chain precursor ENSG0000175189 ///HBC Inbibin beta C chain precursor ENSG0000115144 K/ISS1R KISS1 metastasis-suppressor KISS-1 precursor ENSG00000161614 K/ISS1R KISS1R interceptor precursor ENSG0000016678 LEPR Leptin receptor precursor ENSG0000016678 LEPR Leptin receptor precursor ENSG0000016426 LHB Lutropin-choriogonadotopic hormone receptor precursor ENSG0000015404 K/IT Matty Ender Leptin receptor precursor ENSG0000016426 LHB Lutropin-choriogonadotopic hormone receptor precursor ENSG0000018039 LHCGR Lutropin-choriogonadotopic hormone receptor precursor ENSG000000162624 LHX8 LIWAND MUS protein homolog 4 ENSG0000016425 NAAVD52 Naors protein LN8 ENSG0000016425 NAAVD52 NAORS NAORS Protein homolog 5 ENSG0000014825 NAAVD52 Naors homolog 3 ENSG00000164374 NTAF NALP5 NACH_LR8 and PVD domains-containing protein 5 ENSG0000016430 NBN Nibrin ENSG0000016431 N/BSA1 Steroidoperic factor 1 ENSG0000016431 N/BSA1 Steroidoperic factor 1 ENSG0000016431 N/BSA1 Steroidoperic factor 1 ENSG0000016431 N/BSA1 Steroidoperic factor 1 ENSG0000016431 N/BSA1 Steroidoperic factor 1 ENSG00000167744 NTF4 Neurotropin-4 precursor ENSG00000167748 POR Progetterone receptor component 1 ENSG00000167748 POR NADPH-cytochrome P450 reductase ENSG0000017348 POR NADPH-cytochrome P450 reductase ENSG0000017348 POULFI POU domain, class 5, transcription factor 1 ENSG0000017348 POULFI POU domain, class 5, transcription factor 1 ENSG0000017355 PROP1 Homebox pro	ENSG00000152661	GJA1	Gap junction alpha-1 protein
ENS 60000147437GNRH1Progonadolibern-1 precursorENS 600000123999INHAInhibin alpha chain precursorENS 600000123939INHAInhibin beta A chain precursorENS 60000123033INHBAInhibin beta A chain precursorENS 60000175189INHBCInhibin beta C chain precursorENS 60000170498KISS1Metatasis-suppressor KISS-1 precursorENS 60000170498KISS1Metatasis-suppressor KISS-1 precursorENS 6000017404KITMastYstem cell growth factor receptor precursorENS 60000104826LHBLutropin subunit beta precursorENS 60000104826LHBLutropin subunit beta precursorENS 600000104826LHBLutropin subunit beta precursorENS 600000104826LHBLutropin subunit beta precursorENS 600000104826LHBLutropin subunit beta precursorENS 60000104826LHBLutropin subunit beta precursorENS 60000104826LHBLutropin subunit beta precursorENS 60000104826LHBLutropin subunit beta precursorENS 60000104826NAVMutS protein homolog 5ENS 6000017487NAUPSNACHT, LRR and PYD domains-containing protein 5ENS 6000018756NANOS2Nanos homolog 3ENS 6000018755NANOS2Nanos homolog 3ENS 6000018756NANOS3Nanos homolog 3ENS 6000018756PGRProgesterone receptor component 1ENS 600001127948PORNADPH-cytochrome P450 reductaseENS 600000121879PK3CAPhosphatdylinostich 4, 5-bisphosp	ENSG00000187513	GJA4	Gap junction alpha-4 protein
ENS.G00001199163GMRHMGonadotropin-releasing hormone receptorENS.G0000122641INHAInhibin bata han precursorENS.G0000122641INHBAInhibin bata han precursorENS.G0000175183INHBCInhibin bata C chain precursorENS.G0000176184KISS1Metastasis-suppressor KISS-1 precursorENS.G0000176498KISS1Metastasis-suppressor KISS-1 precursorENS.G0000176498KISS1Metastasis-suppressor KISS-1 precursorENS.G000001617404KITMast/stem cell growth factor receptor precursorENS.G000001637KITLGKITLGENS.G0000016426LI-BLutropin-chorioganadotropic hormone receptor precursorENS.G00000163263LI-CGRLutropin-chorioganadotropic hormone receptor precursorENS.G00000163263MSH4MutS protein homolog 4ENS.G00000163264MSH4MutS protein homolog 4ENS.G0000126410MSH5NACHT, LIR and PVD domains-containing protein 5ENS.G000012748NANOS2Nanos homolog 2ENS.G0000128425NANOS3Nanos homolog 3ENS.G0000128755NANOS3Nanos homolog 3ENS.G0000127744NTF4Neurotropin-4 precursorENS.G0000127748PORProgetrone receptor (RN)ENS.G000012784PORProdection eraceptor (R)ENS.G00000127948PORProdection eraceptor (R)ENS.G0000017386PORMC1Membrane-associated progestrene receptor component 1ENS.G0000017385POU1F1Prodection receptor precursorENS.G0000017384PGE2Pr	ENSG00000147437	GNRH1	Progonadoliberin-1 precursor
ENS.G00000123999INFAInfibin apria Chain precursorENS.G00000163083IN/HBAInhibin beta B chain precursorENS.G00000175189IN/HBCInhibin beta B chain precursorENS.G00000175189IN/HBCInhibin beta C chain precursorENS.G00000175189IN/HBCInhibin beta C chain precursorENS.G00000175404KITMastystem cell growth factor receptor precursorENS.G0000116678LFPRLeptin receptor precursorENS.G0000116678LFPRLeptin receptor precursorENS.G0000116678LHBLutropin-choriognadotropic hormone receptor precursorENS.G0000116678HH3Lutropin-choriognadotropic hormone receptor precursorENS.G000016624LHX8Lutropin-choriognadotropic hormone receptor precursorENS.G0000171487NALP5MutS protein hormolog 4ENS.G0000171487NALP5NACHT, LRR and PYD domains-containing protein 5ENS.G0000188425NANOS2Nanos hormolog 2ENS.G0000188425NANOS2Nanos hormolog 3ENS.G0000187556NANOS2Nanos hormolog 1ENS.G0000167744NTF4Neutortopin-th precursorENS.G000018755PGRProgesterone receptor (PR)ENS.G0000018754PGRProgesterone receptor (PR)ENS.G0000018755PGRProgesterone receptor (PR)ENS.G00000121879PIK3CAPhosphatidylinositol-4,5-bisphosphata-3-kinase catalytic subunit alpha isoformENS.G00000121879PIK3CAPhosphatidylinositol-4,5-bisphosphata-3-hinase catalytic subunit alpha isoformENS.G00000121879 <td>ENSG00000109163</td> <td>GNRHR</td> <td>Gonadotropin-releasing hormone receptor</td>	ENSG00000109163	GNRHR	Gonadotropin-releasing hormone receptor
ENSG0000122641Infinition beta A Chain precursorENSG0000175189INHBENSG0000175189INHBCENSG000011614KISS1Metastasis-uppressor KISS-1 precursorENSG0000116014KISENSG000016014KITENSG00001678LEPRENSG00001678LEPRENSG0000016826LHBENSG00000168264LHBENSG0000015464KITENSG00000168264LHBENSG0000168264LHASENSG0000168264LHASENSG000017487NALPSENSG000017488MSH4MutS protein homolog 4ENSG000017487NALPSENSG000017488NALPSENSG000017487NALPSENSG000016426LHASENSG000017488NANOS2ENSG000017488NANOS2ENSG000017488NANOS3ENSG000016410NOBOXNALPSNIDRINENSG000016410NOBOXENSG000016410NOBOXENSG0000165931NRSA1ENSG0000167744NTF4ENSG0000167744NTF4ENSG000016855PGRNC1ENSG0000171879PK3CAENSG00001721879PK3CAENSG0000172187PALProlactin receptor precursorENSG0000017355PGNP1ENSG0000017355POUSF1POlactin precursorENSG0000017355POC11ENSG0000017355PTS3Prolactin receptor FP2 subtypeENSG0000017355PTS3ENSG0000017355FTS3	ENSG00000123999	INHA	Innibin alpha chain precursor
ENSG000017533InhibitInhibitENSG0000175189II/HBCInhibitENSG0000175189II/HBCInhibitENSG0000116014KISS1Metastais-suppressor KISS-1 precursorENSG0000116014KISS1RKISS-1 receptorENSG0000116014KISII/RENSG00001167404KITMastystem cell growth factor receptor precursorENSG0000116678LEPRLettropin-choriogonadotropic hormone receptor precursorENSG0000138039LHCGRLutropin-choriogonadotropic hormone receptor precursorENSG0000162624LHASUM/homeobox protein Lhv8ENSG00000171487NALP5NACHT, LRR and PYD domains-containing protein 5ENSG0000108425NANOS2Nanos homolog 2ENSG0000108425NANOS2Nanos homolog 3ENSG0000104320NBNNibrinENSG0000104320NBNNibrinENSG000016351NRSA1Steroidogenic factor 1ENSG000011855PGRProgesterone receptor component 1ENSG0000121879PK3CAPhosphatidylinositol-4-5bisphosphate 3-kinase catalytic subunit alpha isoformENSG000001231PORNADPH-cytochrome P450 reductaseENSG000001231PORNADPH-cytochrome P450 reductaseENSG0000012318PORNADPH-cytochrome P450 reductaseENSG0000012318PORNADPH-cytochrome P450 reductaseENSG0000012318PORNADPH-cytochrome P450 reductaseENSG0000012334PTGER2Prostaglandin G/H synthase 2 precusorENSG0000017355PR0F1Pholactin receptor p	ENSG0000162082	INHBA	Innibin beta A chain precursor
ENSOD000175103InfactInfactENSGD0000176498KISS1Metastasis-suppressor KISS-1 precursorENSGD00001614KISS1KISS-1 receptorENSGD0000157404KITMatytem cell growth factor receptor precursorENSGD00001678LEPRLeptin receptor precursorENSGD0000104826LHBLutropin subunit beta precursorENSGD0000162624LHX8LUtropin-choriogonadotropic hormone receptor precursorENSGD0000162624LHX8LUtropin-choriogonadotropic hormone receptor precursorENSGD0000162624LHX8LUtropin subunit beta arecursorENSGD0000162624LHX8LUtropin subunit protein hormolog 4ENSGD000017187NALPSNACHT, LRR and PYD domains-containing protein 5ENSGD00017187NALPSNAcHT, LRR and PYD domains-containing protein 5ENSGD0001017187NALPSNAcHT, LRR and PYD domains-containing protein 5ENSGD0001016310NOBOXNOBOX_HUMAN Isoform 2ENSGD000103631NRSA1Steroidogenic factor 1ENSGD000018556PGRMC1Membrane-associated progesterone receptor component 1ENSG000001857PGRProgesterone receptor (PR)ENSG00000121879PK3CAPhosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha isoformENSG00000123794PORNADPH-cytochrome P450 reductaseENSG00000123744PORNADPH-cytochrome P450 reductaseENSG0000012379PK3CAPhosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha isoformENSG0000012384PORNADPHENSG0	ENSG00000105085	INFIDD	Inhibiti beta 6 chain precursor
EnsoloodNBNHiss-1 receptorENSG00000116014KIS51RKIS5-1 receptorENSG0000049130KITKITENSG0000049130KITKit ligand precursorENSG0000104826LPRLeptin receptor precursorENSG0000138039LHCGRLutropin-choriogonadotropic hormone receptor precursorENSG0000138039LHCGRLutropin-choriogonadotropic hormone receptor precursorENSG0000162624LHX8LIMpomeobox protein Lhx8ENSG0000171487NALP5MutS protein homolog 4ENSG000018425NANOS2Nanos homolog 2ENSG000018425NANOS2Nanos homolog 2ENSG0000104320NBNNibrinENSG000018431NRSA1Steroidogenic factor 1ENSG000011856PGRMC1Memorane-associated progesterone receptor component 1ENSG0000121879PRSCAProgesterone receptor (PR)ENSG0000121879PRSCAProgesterone receptor component 1ENSG00000121879PRSCAProbaphitiositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoformENSG00000121879PRProlactin receursorENSG00000121879PRProlactin receursorENSG00000172179PRLProlactin receursorENSG00000172179PRLProlactin receursorENSG0000017325PCO1Homeobox protein prophet of Pt-1ENSG0000017325PROP1Homeobox protein prophet of Pt-1ENSG0000017325PROP1Homeobox protein prophet of Pt-1ENSG00000173537S/AAD2Protatin recursorENSG000001	ENSG00000170498	KISS1	Metastasis-suppressor KiSS-1 precursor
ENSG00000157404KITMast/stem cell growth factor receptor precursorENSG00000157404KITLGKit ligand precursorENSG00001678LFPRLeptin receptor precursorENSG0000116678LHBLutropin subunit beta precursorENSG00000162624LHASLutropin-choriogonadotropic hormone receptor precursorENSG00000157468MSH4MutS protein hormolog 4ENSG0000017487NALP5NACHT, LRR and PYD domains-containing protein 5ENSG0000187556NANOS2Nanos hormolog 2ENSG00000187556NANOS2Nanos hormolog 3ENSG00000187556NANOS2Nanos hormolog 2ENSG00000187556NANOS2Nanos hormolog 3ENSG00000187556NANOS2Nanos hormolog 3ENSG00000187556NANOS2Nanos hormolog 3ENSG0000108420NBNNibrinENSG00000187556NANOS2Nanos hormolog 3ENSG00000187556PANOS3Nanos hormolog 4ENSG0000018755PGRProgesterone receptor (PR)ENSG0000018631NR5A1Steroidogenic factor 1ENSG0000018756PGRProgesterone receptor (PR)ENSG00000121879PIK3CAPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoformENSG0000017348PORNADPH-cytochrome P450 reductaseENSG0000017349POUPOU domain, class 5, transcription factor 1ENSG0000017344PRLProlactin receptor PrecursorENSG0000017535POUJF1Pholactin receptor PrecursorENSG00000175355POUJF1Prolact	ENSG00000116014	KISST	KiSS-1 recentor
ENSG00000049130K/TLGKit ligand precursorENSG00000116678LEPRLeptin receptor precursorENSG0000014826LHBLutropin-choriogonadotropic hormone receptor precursorENSG00000152624LHX8Lutropin-choriogonadotropic hormone receptor precursorENSG00000204410MSH4MutS protein homolog 4ENSG00000171487NALP5NACHT, LRR and PYD domains-containing protein 5ENSG0000018425NANOS2Nanos homolog 2ENSG000016410NOBOXNOBOXENSG000016410NOBOXNOBOXENSG000016410NOBOXNOBOXENSG0000167744NTF4Neurophin-4 precursorENSG0000167744NTF4Neurophin-4 precursorENSG0000187556PGRProgesterone receptor (PR)ENSG0000187557PGRProgesterone receptor (PR)ENSG000018758PGRProgesterone receptor (PR)ENSG00001167744NTF4Neurotrophin-4 precursorENSG00001167744PGRProgesterone receptor (PR)ENSG0000112757PGRProgesterone receptor (PR)ENSG00000127948PORNADPH-cyclochrome P450 reductaseENSG00000127948PORNADPH-cyclochrome P450 reductaseENSG00000127948POU JF1POLatin precursorENSG0000012799PRLProlactin precursorENSG0000012314PRLProlactin precursorENSG0000012315POU JF1POLatin precursorENSG0000012314PRLProlactin precursorENSG0000012315PROP1Homeobox protein prophet of Pit-	ENSG00000157404	KIT	Mast/stem cell growth factor receptor precursor
ENSG0000116678LEPRLeptin receptor precursorENSG0000104826LHBLutropin subunit beta precursorENSG0000138039LHCGRLutropin-choriogonadotropic hormone receptor precursorENSG00000138039LHCSRLutropin-choriogonadotropic hormone receptor precursorENSG0000026440MSH5MutS protein homolog 4ENSG0000017487NALP5NACHT, LRR and PYD domains-containing protein 5ENSG0000188425NANOS2Nanos homolog 2ENSG0000188425NANOS2Nanos homolog 3ENSG0000188425NANOS2Nanos homolog 3ENSG0000188426NBNNibrinENSG0000188427NBNNibrinENSG0000188426NBOXNOBOXENSG0000188427NRSA1Steroidogenic factor 1ENSG0000188427NRSA1Steroidogenic factor 1ENSG000018931NRSA1Steroidogenic factor 1ENSG000016744NTF4Neurotrophin-4 precursorENSG00000121879PK3CAPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoformENSG00000127948PORNADPH-cytochrome P450 reductaseENSG00000172179PRLProlactin precursorENSG00000172179PRLProlactin precursorENSG0000017382PROP1Homeobox protein prophet of Pit-1ENSG0000017384PGR2Prostaglandin E/r synthase 2 precursorENSG0000017384PTGS2Prostaglandin G/H synthase 2 precursorENSG0000017384PTGS2Prostaglandin G/H synthase 2 precursorENSG0000017385PTGS2Prost	ENSG00000049130	KITLG	Kit ligand precursor
ENS 60000104826LHBLutropin subunit beta precursorENS 60000138039LHCGRLutropin-choriogonadotropic hormone receptor precursorENS 600000162624LHX8LUM/homeobox protein Lhx8ENS 600000057468MSH4MutS protein homolog 4ENS 600000171487NALP5MutS protein homolog 5ENS 60000187556NANOS2Nanos homolog 2ENS 60000164320NBNNibrinENS 60000167744NCBOXNOBOX, HUMAN Isoform 2ENS 60000167745PGRProgesterone receptor (PR)ENS 60000167744NTF4Neurotrophin-4 precursorENS 60000112875PGRProgesterone receptor (PR)ENS 60000121879PKSCAPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoformENS 60000121879PKSCAPhosphatidylinositol-4,4,5-tisphosphate 3-kinase catalytic subunit alpha isoformENS 6000012187POUSF1POU domain, class 5, transcription factor 1ENS 6000017535PROP1Homeobox protein prophet of Pit-1ENS 60000017536<	ENSG00000116678	LEPR	Leptin receptor precursor
ENS 60000138039LHCGRLutropin-choriogonadotropic hormone receptor precursorENS 600000162624LHX8LIM/homeobox protein Lhx8ENS 600000204410MSH4MutS protein homolog 4ENS 600000204410MSH5MutS protein homolog 5ENS 60000171487NALP5NACHT, LRR and PYD domains-containing protein 5ENS 60000188425NANOS2Nanos homolog 2ENS 60000104320NBNNibrinENS 60000106410NOBOXNOBOX_HUMAN Isoform 2ENS 60000166410NOBOXNOBOX_HUMAN Isoform 2ENS 60000167744NTF4Neurotrophin-4 precursorENS 60000127848PGRProgesterone receptor (RR)ENS 60000127849PGRProgesterone receptor (RR)ENS 60000127849PONADCF1ENS 600000127849PORNADPH-cytochrome P450 reductaseENS 60000127849POUPOU domain, class 5, transcription factor 1ENS 60000127849POUPOU domain, class 5, transcription factor 1ENS 60000172179PRLProlactin precursorENS 600000172179PRLProlactin precursorENS 600000173162PTENProlactin precursorENS 60000017382PROP1Homeobox protein prophet of Pt-1ENS 60000017384PTGS2Prostaglandin G/H synthase 2 precursorENS 60000017384PTGS2Prostaglandin G/H synthase 2 precursorENS 60000017384PTGS2Prostaglandin G/H synthase 2 precursorENS 60000017386PTGS2Prostaglandin G/H synthase 2 precursorENS 60000017386PTGS2<	ENSG00000104826	LHB	Lutropin subunit beta precursor
ENSG0000162624LHX8LIM/homeobox protein Lhx8ENSG0000057468MSH4MutS protein homolog 4ENSG00000204410MSH5MutS protein homolog 5ENSG0000171487NALP5NACHT, LRR and PYD domains-containing protein 5ENSG0000187556NANOS2Nanos homolog 3ENSG0000187556NANOS3Nanos homolog 3ENSG0000167140NOBOXNOBOX_LIVIAN Isoform 2ENSG0000167744NTF4Neutrotrophin-4 precursorENSG000018556PGRProgesterone receptor (PR)ENSG000018556PGRProgesterone receptor (PR)ENSG000011856PGRMC1Membrane-associated progesterone receptor component 1ENSG0000121879PIK3CAPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoformENSG000001721879PIK3CAPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoformENSG00000172179PRLProlactin precursorENSG00000172179PRLProlactin precursorENSG0000017325PROP1Homeobox protein probet of Pit-1ENSG0000017325PROP1Homeobox protein prophet of Pit-1ENSG0000017325PTGER2Prostaglandin G/H syntase 2 precursorENSG0000017356PTGS2Prostaglandin E z receptor PP2 subtypeENSG0000017355SMAD1Mothers against decapentaplegic homolog 1ENSG000017356SMAD1Mothers against decapentaplegic homolog 1	ENSG00000138039	LHCGR	Lutropin-choriogonadotropic hormone receptor precursor
ENSG0000057468MSH4MutS protein homolog 4ENSG00000204410MSH5MutS protein homolog 5ENSG0000171487NALP5NACHT, LRR and PYD domains-containing protein 5ENSG0000171487NANOS2Nanos homolog 2ENSG0000104320NBNNibrinENSG000016610NOBOXNOBOX_HUMAN Isoform 2ENSG00000167744NTF4Neurotrophin-4 precursorENSG00000167744NTF4Neurotrophin-4 precursorENSG00000121856PGRProgesterone receptor (PR)ENSG00000121879PIK3CAPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoformENSG00000121879PIK3CAPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoformENSG000001217948PORNADPH-cytochrome P450 reductaseENSG00000172179PRLProlactin precursorENSG00000172179PRLProlactin precursorENSG00000173255PROP1Homeobox protein prophet of Pit-1ENSG00000175384PTGF22Prostaglandin E, receptor F2 subtypeENSG0000017356PTGS2Prostaglandin E, receptor F2 subtypeENSG0000017356PTGS2Prostaglandin E, receptor F2 subtypeENSG0000017365SMAD1Mothers against decapentaplegic homolog 1ENSG0000175377SMAD2Mothers against decapentaplegic homolog 1	ENSG00000162624	LHX8	LIM/homeobox protein Lhx8
ENSG00001204410MSH5MutS protein homolog 5ENSG00000171487NALP5NACHT, LRR and PYD domains-containing protein 5ENSG0000188425NANOS2Nanos homolog 2ENSG0000104820NBNNibrinENSG0000106410NOBOXNOBOX_HUMAN Isoform 2ENSG0000016531NR5A1Steroidogenic factor 1ENSG0000018556PGRProgesterone receptor (PR)ENSG0000011856PGRProgesterone receptor component 1ENSG00000121879PIK3CAPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoformENSG00000127948PORNADPH-cytochrome P450 reductaseENSG00000172179PRLProlactin precursorENSG00000172179PRLProlactin precursorENSG00000172179PRLProlactin precursorENSG00000172179PRLProlactin precursorENSG00000172179PRLProlactin precursorENSG0000017384POCP1Homeobox protein prophet of Pit-1ENSG0000017385PTGS2Prostaglandin E ₂ receptor EP2 subtypeENSG0000017384PTGS2Prostaglandin E ₂ receptor EP2 subtypeENSG0000017385PTGS2Prostaglandin G/H synthase 2 precursorENSG0000017365SMAD1Mothers against decapentaplegic homolog 1ENSG00000175387SMAD2Mothers against decapentaplegic homolog 2	ENSG0000057468	MSH4	MutS protein homolog 4
ENSG0000171487NALP5NACH1, LRR and PYD domains-containing protein 5ENSG00000188425NANOS2Nanos homolog 2ENSG00001187556NANOS3Nanos homolog 3ENSG0000104320NBNNibrinENSG0000136931NRSA1Steroidogenic factor 1ENSG0000167744NTF4Neurotrophin-4 precursorENSG0000121875PGRProgesterone receptor (PR)ENSG00000121879PIK3CAPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoformENSG00000121879PIK3CAPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoformENSG00000121879PIK3CAPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoformENSG0000121879PIK3CAPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoformENSG00000121879PIK3CAPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoformENSG0000121879PIK3CAPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoformENSG0000172179PRLProlactin precursorENSG0000175325PROP1Homeobox protein prophet of Pit-1ENSG0000175325PROP1Homeobox protein prophet af pit-1ENSG00000125384PTGER2Prostaglandin E2 receptor EP2 subtypeENSG00000163661PTX3Pentraxin-related protein PTX3 precursorENSG0000173365SMAD1Mothers against decapentaplegic homolog 1ENSG0000175387SMAD2Mothers against decapentaplegic homolog 2	ENSG0000204410	MSH5	MutS protein homolog 5
ENSG0000188425NANOS2Nanos homolog 2ENSG0000187556NANOS3Nanos homolog 3ENSG0000104320NBNNibrinENSG000016410NOBOXNOBOX_HUMAN Isoform 2ENSG0000167744NR5A1Steroidogenic factor 1ENSG0000018755PGRProgesterone receptor (PR)ENSG000011856PGRMC1Membrane-associated progesterone receptor component 1ENSG0000127948PORNADPH-cytochrome P450 reductaseENSG00000127948POUF1Pituitary-specific positive transcription factor 1ENSG00000127948POUF1Pituitary-specific positive transcription factor 1ENSG00000127948POUF1Pituitary-specific positive transcription factor 1ENSG00000127532PRLProlactin precursorENSG00000175325PROP1Homeobox protein prophet of Pit-1ENSG00000125384PTGER2Prostaglandin E2 receptor EP2 subtypeENSG00000125384PTGS2Prostaglandin G/H synthase 2 precursorENSG0000163661PTX3Pentraxin-related protein PTX3 precursorENSG000017365SMAD1Mothers against decapentaplegic homolog 1ENSG0000175387SMAD2Mothers against decapentaplegic homolog 2	ENSG00000171487	NALP5	NACHT, LRR and PYD domains-containing protein 5
ENSG0000018356IVANOS3Nanos homolog 3ENSG00000104320NBNNibrinENSG00000104320NBNNibrinENSG0000016410NOBOXNOBOX_HUMAN Isoform 2ENSG00000167744NTF4Neurotrophin-4 precursorENSG000001856PGRProgesterone receptor (PR)ENSG00000121879PIK3CAPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoformENSG00000127948PORNADPH-cytochrome P450 reductaseENSG000001721948PORNADPH-cytochrome P450 reductaseENSG00000172179PRLProlactin precursorENSG00000172179PRLProlactin precursorENSG00000172179PRLProlactin precursorENSG00000175325PROP1Homeobox protein prophet of Pit-1ENSG00000125384PTGER2Prostaglandin E2 receptor EP2 subtypeENSG0000016251PTGS2Prostaglandin E2 receptor EP2 subtypeENSG00000172376PTGS2Prostaglandin G/H synthase 2 precursorENSG0000016218RSP01R-spondin-1 precursorENSG000017365SMAD1Mothers against decapentaplegic homolog 1ENSG000017387SMAD2Mothers against decapentaplegic homolog 1	ENSG00000188425	NANOS2	Nanos homolog 2
ENSG00000104320NBNNBNENSG00000106410NOBOXNOBOXENSG00000136931NR5A1Steroidogenic factor 1ENSG00000167744NTF4Neurotrophin-4 precursorENSG000001856PGRProgesterone receptor (PR)ENSG00000121879PIK3CAPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoformENSG00000127948PORNADPH-cytochrome P450 reductaseENSG000001721879PIK3CAPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoformENSG00000127948PORNADPH-cytochrome P450 reductaseENSG00000172179PRLProlactin precursorENSG00000172179PRLProlactin precursorENSG00000175325PROP1Homeobox protein prophet of Pit-1ENSG00000125384PTGER2Prostaglandin E2 receptor EP2 subtypeENSG00000125384PTGS2Prostaglandin G/H synthase 2 precursorENSG00000163661PTX3Pentraxin-related protein PTX3 precursorENSG000017355SMAD1Mothers against decapentaplegic homolog 1ENSG000017387SMAD2Mothers against decapentaplegic homolog 2	ENSG0000104220	NANUS3	Nanos nomolog 3
ENSG00000136910NOBOXNOBOXENSG00000136911NRSA1Steroidogenic factor 1ENSG0000013691NRSA1Steroidogenic factor 1ENSG0000082175PGRProgesterone receptor (PR)ENSG0000121879PIK3CAPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoformENSG00000127948PORNADPH-cytochrome P450 reductaseENSG00000172948POU1F1Pituitary-specific positive transcription factor 1ENSG00000172179PRLProlactin precursorENSG00000172179PRLProlactin precursorENSG00000175325PROP1Homeobax protein prophet of Pit-1ENSG00000125384PTGER2Prostaglandin E2 receptor EP2 subtypeENSG00000125384PTGS2Prostaglandin G/H synthase 2 precursorENSG00000136611PTX3Pentraxin-related protein PTX3 precursorENSG0000017365SMAD1Mothers against decapentaplegic homolog 1ENSG0000175387SMAD2Mothers against decapentaplegic homolog 2	ENSG00000104320		
ENSG00000167744NTFADecoder of the function o	ENSG0000136931	NR5A1	Steroidogenic factor 1
ENSG0000082175PGRProgesterone receptor (PR)ENSG0000011856PGRMC1Membrane-associated progesterone receptor component 1ENSG00000121879PIK3CAPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoformENSG00000127948PORNADPH-cytochrome P450 reductaseENSG00000204531POUJF1Pituitary-specific positive transcription factor 1ENSG00000172179PRLProlactin precursorENSG00000175325PROP1Prolactin receptor precursorENSG00000175325PROP1Homeobox protein prophet of Pit-1ENSG00000125384PTGER2Prostaglandin E2 receptor EP2 subtypeENSG00000163661PTX3Pentraxin-related protein PTX3 precursorENSG00000163651SMAD1Mothers against decapentaplegic homolog 1ENSG00000175387SMAD2Mothers against decapentaplegic homolog 2	ENSG00000167744	NTF4	Neurotrophin-4 precursor
ENSG00000101856PGRMC1Membrane-associated progesterone receptor component 1ENSG00000121879PIK3CAPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoformENSG00000127948PORNADPH-cytochrome P450 reductaseENSG00000064835POU1F1Pituitary-specific positive transcription factor 1ENSG00000172179PRLPOU domain, class 5, transcription factor 1ENSG00000172179PRLProlactin precursorENSG0000017255PROP1Homeobox protein prophet of Pit-1ENSG00000125384PTGER2Prostaglandin E2 receptor EP2 subtypeENSG0000013561PTX3Pentraxin-related protein PTX3 precursorENSG0000013661PTX3Pentraxin-related protein PTX3 precursorENSG00000175355SMAD1Mothers against decapentaplegic homolog 1ENSG00000173756SMAD2Mothers against decapentaplegic homolog 2	ENSG0000082175	PGR	Progesterone recentor (PR)
ENSG0000121879 <i>PIK3CA</i> Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoformENSG00000127948 <i>POR</i> NADPH-cytochrome P450 reductaseENSG0000064835 <i>POU1F1</i> Pituitary-specific positive transcription factor 1ENSG00000204531 <i>POU5F1</i> POU domain, class 5, transcription factor 1ENSG00000172179 <i>PRL</i> Prolactin precursorENSG00000175325 <i>PROP1</i> Homeobox protein prophet of Pit-1ENSG00000175384 <i>PTGER2</i> Prostaglandin E2 receptor EP2 subtypeENSG00000175365 <i>PTGS2</i> Prostaglandin G/H synthase 2 precursorENSG00000169218 <i>RSPO1</i> R-spondin-1 precursorENSG0000170365 <i>SMAD1</i> Mothers against decapentaplegic homolog 1ENSG0000175387 <i>SMAD2</i> Mothers against decapentaplegic homolog 2	ENSG00000101856	PGRMC1	Membrane-associated progesterone receptor component 1
ENSG00000127948PORNADPH-cytochrome P450 reductaseENSG0000064835POU1F1Pituitary-specific positive transcription factor 1ENSG00000204531POU5F1POU domain, class 5, transcription factor 1ENSG00000172179PRLProlactin precursorENSG00000175325PROP1Homeobox protein prophet of Pit-1ENSG00000175325PTENPhosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphataseENSG00000125384PTGER2Prostaglandin E2 receptor EP2 subtypeENSG00000163661PTX3Pentraxin-related protein PTX3 precursorENSG0000170365SMAD1Mothers against decapentaplegic homolog 1ENSG0000175387SMAD2Mothers against decapentaplegic homolog 2	ENSG00000121879	РІКЗСА	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
ENSG0000064835POU1F1Pituitary-specific positive transcription factor 1ENSG0000204531POU5F1POU domain, class 5, transcription factor 1ENSG0000172179PRLProlactin precursorENSG0000113494PRLRProlactin receptor precursorENSG0000175325PROP1Homeobox protein prophet of Pit-1ENSG00000175826PTENProstaglandin E2 receptor EP2 subtypeENSG00000175384PTGER2Prostaglandin G/H synthase 2 precursorENSG00000163661PTX3Pentraxin-related protein PTX3 precursorENSG0000169218RSPO1R-spondin-1 precursorENSG0000170365SMAD1Mothers against decapentaplegic homolog 1ENSG0000175387SMAD2Mothers against decapentaplegic homolog 2	ENSG00000127948	POR	NADPH-cytochrome P450 reductase
ENSG0000204531POU5F1POU domain, class 5, transcription factor 1ENSG0000172179PRLProlactin precursorENSG0000113494PRLRProlactin receptor precursorENSG0000175325PROP1Homeobox protein prophet of Pit-1ENSG00000171862PTENProsphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphataseENSG00000125384PTGER2Prostaglandin E2 receptor EP2 subtypeENSG00000163661PTX3Pentraxin-related protein PTX3 precursorENSG00000169218RSPO1R-spondin-1 precursorENSG0000170365SMAD1Mothers against decapentaplegic homolog 1ENSG0000175387SMAD2Mothers against decapentaplegic homolog 2	ENSG0000064835	POU1F1	Pituitary-specific positive transcription factor 1
ENSG00000172179PRLProlactin precursorENSG00000113494PRLRProlactin receptor precursorENSG00000175325PROP1Homeobox protein prophet of Pit-1ENSG00000171862PTENPhosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphataseENSG00000125384PTGER2Prostaglandin E2 receptor EP2 subtypeENSG00000163661PTX3Pentraxin-related protein PTX3 precursorENSG00000169218RSPO1R-spondin-1 precursorENSG00000170365SMAD1Mothers against decapentaplegic homolog 1ENSG00000175387SMAD2Mothers against decapentaplegic homolog 2	ENSG00000204531	POU5F1	POU domain, class 5, transcription factor 1
ENSG00000113494PRLRProlactin receptor precursorENSG00000175325PROP1Homeobox protein prophet of Pit-1ENSG00000171862PTENPhosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphataseENSG00000125384PTGER2Prostaglandin E2 receptor EP2 subtypeENSG0000013756PTGS2Prostaglandin G/H synthase 2 precursorENSG00000163661PTX3Pentraxin-related protein PTX3 precursorENSG00000170365SMAD1Mothers against decapentaplegic homolog 1ENSG00000175387SMAD2Mothers against decapentaplegic homolog 2	ENSG00000172179	PRL	Prolactin precursor
ENSG00000175325PROP1Homeobox protein prophet of Prt-1ENSG00000175325PTENPhosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphataseENSG00000125384PTGER2Prostaglandin E2 receptor EP2 subtypeENSG0000073756PTGS2Prostaglandin G/H synthase 2 precursorENSG00000163661PTX3Pentraxin-related protein PTX3 precursorENSG00000169218RSPO1R-spondin-1 precursorENSG00000170365SMAD1Mothers against decapentaplegic homolog 1ENSG00000175387SMAD2Mothers against decapentaplegic homolog 2	ENSG00000113494	PRLR	Prolactin receptor precursor
ENSG00000171862PTENPhosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphataseENSG00000125384PTGER2Prostaglandin E2 receptor EP2 subtypeENSG0000073756PTGS2Prostaglandin G/H synthase 2 precursorENSG00000163661PTX3Pentraxin-related protein PTX3 precursorENSG00000169218RSPO1R-spondin-1 precursorENSG00000170365SMAD1Mothers against decapentaplegic homolog 1ENSG00000175387SMAD2Mothers against decapentaplegic homolog 2	ENSG00000175325	PROP1	Homeobox protein prophet of Pit-1
ENSG00000125384PTGER2Prostaglandin E2 receptor EP2 subtypeENSG0000073756PTGS2Prostaglandin G/H synthase 2 precursorENSG00000163661PTX3Pentraxin-related protein PTX3 precursorENSG00000169218RSPO1R-spondin-1 precursorENSG00000170365SMAD1Mothers against decapentaplegic homolog 1ENSG00000175387SMAD2Mothers against decapentaplegic homolog 2	ENSG00000171862	PIEN	Phosphatidy(inositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity
ENSG00000123504PTGER2PToStaglandin E2 receptor EP2 subtypeENSG00000073756PTGS2Prostaglandin G1 H synthase 2 precursorENSG00000163661PTX3Pentraxin-related protein PTX3 precursorENSG00000169218RSP01R-spondin-1 precursorENSG00000170365SMAD1Mothers against decapentaplegic homolog 1ENSG00000175387SMAD2Mothers against decapentaplegic homolog 2		DTCEDO	protein phosphatase Prostaglandin E., recentor EP2 subtring
ENSG00000163661PTX3Pentraxin-related protein PTX3 precursorENSG00000169218RSP01R-spondin-1 precursorENSG00000177365SMAD1Mothers against decapentaplegic homolog 1ENSG00000175387SMAD2Mothers against decapentaplegic homolog 2	ENSG00000125584	PTGS2	Prostaglandin G/H synthese 2 productor
ENSG00000169218RSP01R-spondin-1 precursorENSG00000177365SMAD1Mothers against decapentaplegic homolog 1ENSG00000175387SMAD2Mothers against decapentaplegic homolog 2	ENSG00000163661	PTX3	Pentraxin-related protein PTX3 precursor
ENSG00000170365SMAD1Mothers against decapentaplegic homolog 1ENSG00000175387SMAD2Mothers against decapentaplegic homolog 2	ENSG00000169218	RSPO1	R-spondin-1 precursor
ENSG00000175387 SMAD2 Mothers against decapentaplegic homolog 2	ENSG00000170365	SMAD1	Mothers against decapentaplegic homolog 1
	ENSG00000175387	SMAD2	Mothers against decapentaplegic homolog 2

TABLE 1

Cont	inued.	
Some	mucu.	

Ensembl ID	Gene name	Description
ENSG00000166949	SMAD3	Mothers against decapentaplegic homolog 3
ENSG00000113658	SMAD5	Mothers against decapentaplegic homolog 5
ENSG00000142168	SOD1	Superoxide dismutase
ENSG00000147465	STAR	Steroidogenic acute regulatory protein, mitochondrial precursor

Note: Ensembl ID refers to the genomic sequence code from the Ensembl database (http://www.ensembl.org).

Fonseca. NGS and potential new POF genes. Fertil Steril 2015.

reference genome GRCh37/hg19 was used for mapping exome sequencing (Exome-Seq). The sequence database downloaded from the ensembl website (http://www.ensembl.org/Homo_ sapiens/Info/Index) was used as our gene model and for determining amino acid substitutions. Raw data obtained from Illumina GAII and SeqQC (in-house tool) were used for checking data quality. Low quality and adaptor contamination were filtered using BLAT software (in-house tool). The high-quality filtered data were further aligned with the human reference genome using BWA 0.5.9rcl software (http://bio-bwa.source forge.net/), and variants were identified using samtools-0.1.7a (http://samtools.sourceforge.net/). The variants were then filtered on the basis of read depth and mapping quality. The filtered variations were annotated, along with their potential effect, by using snpEFF 3.4i software (http://snpeff. sourceforge.net/). The results were compared with dbSNP database data (NCBI version db137). This led to identifying novel variations and their effect. Annotated variations were further reviewed manually. Genotypic Technology did the exome sequencing and primary data analysis. Excel functions were used for subsequent filtering.

ADAMTS19 (gi|112789555), BMPR2 (gi|15451916), and LHCGR (gi|106067657) human wild type sequences were used for multiple protein alignment (ClustalW software) for studying conservation during the evolution of interchanged residues (candidate mutations). These sequences were aligned with those from distinct vertebrate species (Supplemental Table 1).

PolyPhen2 and SIFT bioinformatics tools were used for assessing potentially damaging effects. PolyPhen2 prediction values resulted from an algorithm using comparative analysis of protein sequences from different species, the exchanged amino acids physicochemical characteristics, and mapping residue replacement regarding available three-dimensional structures. The results are assessed as benign, probably damaging, or possibly damaging (30). The SIFT program uses amino acid hydrophobic features and conservation among species (protein sequence similarity) to establish the probability of deleterious effects caused by missense mutations (31). A score under 0.05 would argue in favor of pathogenicity.

Sanger Sequencing

ADAMTS19 (ENST00000274487) exon 19, *BMPR2* (ENST00000374580) exon 13, and *LHCGR* (ENST0000029 4954) exons 3 and 6 were amplified by PCR from relevant patients to confirm potentially deleterious candidate sequence variants obtained from NGS assays (see below and Table 2)

by using exon-flanking primers. Amplicons were purified using shrimp alkaline phosphatase and exonuclease I, following the manufacturer's instructions. Direct sequencing was performed with internal primers using a capillary sequencer (Applied Biosystems). Primer sequences and PCR conditions are available upon request. An identical experimental setup was used for screening these sequence variants in control individuals and in the GP group. Familial segregation of *BMPR2* and *LHCGR* mutations found in the POF19 patient was screened in some members of her family (II:1, II:2, II:3, III:3, from Supplemental Fig. 1).

RESULTS

NGS and in Silico Analysis

NGS assays produced ~2.5 GB data for 12 samples for each individual as pair-end reads, having up to 97 bp mean read length, and about 90% (0.2 Mb length) of the targeted bases were covered, thereby sufficiently passing our thresholds for calling single nucleotide polymorphisms (SNPs) and short insertions or deletions (indels). Excel filtering of sequence variants revealed five heterozygous coding variants: ADAMTS19 c.2828C \rightarrow T (p.Thr943lle), *LHCGR* c.296A \rightarrow G (p.Asn99Ser), *LHCGR* c.526C \rightarrow T (p.Ser176Pro), *BMPR2* c.2960C \rightarrow T (p.Ser987Phe), and *NR5A1* c.1195G \rightarrow T (p.Ala399Ser).

The POF7 patient had the ADAMTS19-Thr943lle mutation, the POF19 patient had LHCGR-Asn99Ser and BMPR2-Ser987Phe mutations, and the POF23 and POF136 women were carriers of the LHCGR-Ser176Pro and NR5A1-Ala399Ser mutations, respectively.

Multiple protein alignment showed that all interchanged amino acids were conserved among vertebrate species (data not shown). SIFT and PolyPhen predictions have been included in Table 2.

Direct Sequencing of Candidate Mutations

The confirmation step for NGS results (via Sanger sequencing) revealed that four out of five variants (*ADAMTS19* c.2828C \rightarrow T, *LHCGR* c.296A \rightarrow G, *LHCGR* c.526C \rightarrow T, and *BMPR2* c.2960C \rightarrow T) were definitely present in the corresponding patients (Fig. 1 and Table 2). The *NR5A1* c.1195G \rightarrow T sequence variant was not present in the POF136 patient, thus displaying an NGS artifact. The aforementioned positive variants were not found in the CG and GP groups. Therefore, the allele frequency for each variant was as follows: POF group, 1/24; CG, 0/352; GP group,

TABLE 2

Clinical features and molecular findings.

Patient	POF7	POF19	POF23
Clinical features			
Actual age	29	36	30
Amenorrhea	Secondary	Secondary	Secondary
FSH, IU/L	96.2	130	90.4
LH, IU/L	58.1	19.6	20.8
E ₂ pg/mL	38	9.8	16
Molecular findings			
Gene	ADAMTS 19	BMPR2	LHCGR
		LHCGR	
Sequence variation	c.2828C>T	BMPR2-c.2960C>T	c.526T>C
		LHCGR-c.296A>G	
AA change	Thr943lle	BMPR2-Ser987Phe	Ser176Pro
		LHCGR-Asn99Ser	
Pathogenicity prediction			
SIFT	0,32	BMPR2-Ser987Phe: 0,00	0,03
		LHCGR-Asn99Ser: 0,26	
PolyPhen	Possibly damaging	BMPR2-Ser987Phe: Possibly damaging LHCGR-Asn99Ser: Bening	Bening

Note: Clinical features include details on reproductive conditions of POF patients presenting potential pathogenic mutations. Molecular and in silico results suggest deleterious effects of missense mutations. AA = amino acid.

Fonseca. NGS and potential new POF genes. Fertil Steril 2015.

0/690. Family members of POF19 patient were carriers of the *BMPR2* c.2960A \rightarrow G (II:3, III:3) or *LHCGR* c.296A \rightarrow G (II:1, II:2) sequence variant. Only the POF19 individual (III:5) displayed both variants at the heterozygous state (Supplemental Fig. 1).

irregular cycles for 1 year, rapidly evolving to amenorrhea. Transvaginal ultrasound reported normal uterus and ovaries. FSH, LH, and E_2 plasma levels at 29 years of age were, respectively, 96.2 IU/L, 58.1 IU/L, and 38 pg/mL (normal ranges: FSH, 4–13 IU/L; LH, 2–15 IU/L; E_2 , 20–145 pg/mL). Antithyroid and anti-DNA serum antibodies were undetectable. She did not refer to a family background of fertility disorders.

Patients' Phenotype

ADAMTS19- p.Thr943lle mutation. The POF7 woman had experienced menarche at 12 years of age and had normal menstrual cycles (25 days) until the age of 28. Then she had

BMPR2-Ser987Phe and LHCGR-Asn99Ser mutations. The POF19 patient was a 37-year-old woman who was affected by amenorrhea, hot flushes, and dizziness. Menarche had occurred at 11 years of age with regular menstrual cycles



Chromatograms of POF patients presenting ADAMTS19, BMPR2, and LHCGR mutations. (A) POF7 patient: ADAMTS19-c.2828C>T mutation. (B) POF19 patient: BMPR2 c.2960C>T and LHCGR-c.296A>G. (C) POF23 patient: c.526T>C. WT = wild type sequences. Arrows indicate positions of heterozygous mutations.

(every 28 days). When the menses stopped, her FSH, LH and E_2 levels were, respectively, 130 IU/L, 19.6 IU/L, and 9.8 pg/mL. Antithyroid and anti-DNA serum antibodies were undetectable. She did not mention symptoms evoking cardiac or pulmonary dysfunction. Physical examination did not reveal any clinical signs of pulmonary hypertension. Chest radiograph and transthoracic echocardiogram gave normal results. No family background of hypofertility or further diseases was recorded.

LHCGR-p.Ser176Pro mutation. The patient carrying the LHCGR-p.Ser176Pro was a 30-year-old woman who presented with secondary amenorrhea. She had experienced menarche at the age of 12, with irregular menstrual cycles. However, she did become pregnant and had one child. She had no family background of reproductive disease. Transvaginal ultrasound did not reveal any morphological abnormalities of the reproductive tract. Paraclinical tests showed increased FSH plasma levels (90.4 IU/L), as well as low LH (20.8 IU/L) and E_2 levels (16 pg/mL). Antithyroid and anti-DNA serum antibodies were undetectable.

DISCUSSION

Human infertility can be considered to be a public health concern since up to 15% of couples are affected by this disorder. Distinct conditions, such as tubal dysfunction, endometriosis, and ovarian pathology, have been recorded as exclusively female etiological factors. It has been estimated that \sim 15% of women have dysfunctions leading to reduced ovarian reserve and, eventually, to POF (32). To date, mutations in only a few genes have been definitely related to POF pathogenesis, owing to Sanger sequencing's technical limitations regarding the polygenic nature of reproductive phenotypes.

To overcome such drawbacks in the present study, the complete coding regions of 70 candidate genes were massively sequenced, via NGS, in 12 patients with POF (Table 1). Several characteristics were considered when including specific genes in the sequencing microarray, such as previous reported tests validating a functional role, coherent spatiotemporal expression pattern, positive genetic association studies, and animal models having similar to POF phenotypes. These genes belong to molecular pathways that are involved in distinct steps regarding gonad development and ovarian physiology, such as sex determination, meiosis, folliculogenesis, and ovulation. It should be noted that, since we used a 244K microarray, our approach probably did not encompass all POF candidate genes (e.g., more than 350) (33-37). However, our results indicated that 25% (3/12)of patients (POF7, POF19, and POF23) carried mutations that potentially contribute to disease pathogenesis.

The POF7 patient, who was affected by secondary amenorrhea, was a carrier of the *ADAMTS19*-c.2828C \rightarrow T heterozygous sequence variant (Fig. 1). Human *ADAMTS19*, which is located on chromosome 5, encodes a zinc metalloprotease from the 19-member ADAMTS (a disintegrin and metalloproteinase having thrombospondin motifs) family of proteins (38). At the structural level, ADAMTS factors have distinct domains, motifs, and modules (38–40). These include (from the

N-ter to the C-Ter regions) a signal peptide, a prodomain, a metalloproteinase domain, a disintegrin-like domain, a central thrombospondin type I-like (TS) repeat, a cysteine-rich domain, a spacer region, and a C-terminal region having a variable number of TS repeats (39). ADAMTS19, like other members of the family, includes an additional region, the PLAC (protease and lacunin) domain, located in the protein's C-terminal region. It has been shown (by phylogenetic analysis) that ADAMTS17 is the closest related member to ADAMTS19 (38, 39, 41).

Although specific ADAMTS19 expression has not been widely studied, it has been detected in an osteosarcoma cDNA library and in fetal lung (38). Low expression signals have been reported in developing heart, kidney, skeletal muscle, and testis (42, 43). Adamts19 expression in mouse XX gonads has been observed at E10.5 and from E12.5 to E15.5 as well as in postnatal life (8 days postpartum) (42, 44). It is interesting that ovarian somatic cells expressing specific markers (e.g., Follistatin and Foxl2) also express Adamts19 (42, 43). ADAMTS19's function remains unknown, but, similar to other family members, it might contribute to extracellular matrix remodeling by proteolytic activity on specific substrates, such as proteoglycans and fibrillar collagens (45). Concerning POF, it has been reported (using genome-wide SNP genotyping) that ADAMTS19 might be associated with the phenotype (46). Furthermore, some ADAMTS19 sequence variants seem to be associated with ACVR2B and IGF2R SNPs, which might confer increased susceptibility to POF (47, 48).

The ADAMTS19 mutation (c.2828C \rightarrow T, p.Thr943Ile mutation) found in our patient is novel, since it has not been described in public SNP databases and it was not present in 176 women from the CG. Furthermore, we could not find it in 345 women (690 alleles) from the GP, suggesting that it might be a rare causative variant. In silico analysis at the protein level showed that the interchanged threonine residue in position 943 was highly conserved among vertebrate species, thereby underlining a putative functional role. Regarding physicochemical properties, the presence of an isoleucine instead of a threonine is predicted to modify protein structure and hydrophobicity. In fact, Thr is a small, polar amino acid having hydrophilic properties, while Ile is a large, nonpolar hydrophobic residue. Such differences might alter protein folding and its function. Accordingly, PolyPhen2 predicted a deleterious effect ("possibly damaging" score). SIFT did not suggest a pathogenic consequence (score, 0.32), and it should be stressed that both PolyPhen2 and SIFT bioinformatics tools estimate only predictions regarding missense variants' potentially deleterious effects. PolyPhen2 and SIFT involve using some similar features, such as alignments methods, to propose potential deleterious effects. However, they automatically explore distinct Internet databases containing differing quality sequences for a specific protein. This leads, in some cases, to contradictory results, as well as to imprecise predictions. For instance, if, for a specific protein, a significant number of noncurated sequences (background noise) from other species are taken for analysis, it is highly probable that negative (harmless) predictions will be obtained for a particular missense mutation. On the contrary, if only a few well-described sequences from closely related species (e.g., humans and chimpanzees) are used for calculations, then false-positive predictions could be found. Positive or negative results would certainly be considered as a part of a more comprehensive analysis including protein alignment, mutation localization in a protein's functional domains, and examining mutation-induced physicochemical changes. The p.Thr943Ile mutation is located in the first TS repeat in the protein's C-terminal region. Interestingly, it has been shown that the C-terminal region of some ADAMTS proteins (e.g., ADAMTS1, ADAMTS4) is necessary for both substrate specificity and localization (39 and references therein, 40). We thus hypothesized that the p.Thr943Ile mutation might alter ADAMTS19 substrate-binding properties and modify enzyme selectivity. The mutant protein could also display abnormal cell/tissue localization. Such features regarding an ovarian context might be linked to abnormal somatic cells' extracellular matrix turnover, leading to defects in follicular development and thus to POF. It would be interesting to perform in vitro functional tests to validate this hypothesis as well as to create pertinent Adamts19 mouse models (e.g., knockout, knock-in).

The POF19 patient, who was affected by secondary amenorrhea, had two heterozygous coding variants in BMPR2 and LHCGR genes (Fig. 1). BMPR2 (bone morphogenetic protein receptor type II) encodes a serine-threonine kinase, which is responsible for binding bone morphogenetic proteins (BMP) (49, 50). BMP factors belong to the TGF- β superfamily of growth factors, which are involved in a wide variety of biological processes, including reproduction (51). After secretion to the extracellular space, BMP ligands bind to transmembrane type II receptors, which in turn transphosphorylate type I receptors (52). Type I receptor activation leads to SMAD protein phosphorylation and then to nuclear translocation of signaling for regulating target genes (53). BMP15 and GDF9 ligands, two key actors in ovarian physiology, have been related to BMPR2 activation in mice and humans (54-56). In these species, BMP15:GDF9 heterodimers (produced by oocytes) have higher biological activity than homodimers (BMP15:BMP15 or GDF9:GDF9). It has been shown that BMP15:GDF9 heterodimers act via the BMPR2-ALK4/5/7-ALK6 receptor complex located in granulosa cells (56). Since BMP15 sequence variants have been related to POF etiology, we estimate that BMPR2 coding mutations might also cause the disease (6, 17, 57). The heterozygous mutation found in our patient strongly suggested a deleterious effect since it was not present in our control population groups and it displays a minimal allele frequency <.01 (rs150642992). In silico analysis has shown that the BMPR2 p.Ser987Phe mutation affects a highly evolutionary conserved residue during evolution. SIFT and PolyPhen2 predictions agreed with such an assumption (SIFT, 0.00; PolyPhen2, probably damaging; Table 2). At the physicochemical level, the p.Ser987Phe mutation implies a drastic effect because serine is a small, polar amino acid, while phenylalanine is a large, aromatic residue. This mutation affects the transmembrane receptor's intracellular C-terminal tail region, which interacts with proteins involved in cellular features such as ion transport,

transcription, cytoskeleton structure/modulation, and trafficking (58-60). Furthermore, this region might affect SMAD intracellular signaling, and we thus hypothesize that the BMPR2-p.Ser987Phe mutation in granulosa cells might interfere with BMP15 downstream signaling, thereby contributing to POF etiology. It should be noted that BMPR2 encoding mutations (most being nonsense mutations) have been related to primary pulmonary hypertension (PPH), a disease having an autosomal dominant inheritance pattern (61-65). Our patient had no clinical signs or background of PPH, which might be explained by the disease's low penetrance (20%-30%) (64). Concerning individuals with PPH, an association with POF has not been reported to date, probably because it has not been systematically explored or reported.

POF19 patient is also affected by the heterozygous *LHCGR* c.296A \rightarrow G (p.Asn99Ser) mutation. As for the ADAMTS19 and BMPR2 mutations described above, control population screening and bioinformatics studies suggested a potentially deleterious effect. This mutation, located in the protein's extracellular domain, is novel and affects an amino acid that is conserved during vertebrate species' evolution. LHCGR and FSHR were the first genes for which coding mutations were related to POF (7, 8). Only homozygous mutations in these genes in XX women have been definitely linked to POF etiology. However, this feature does not rule out heterozygous variants contributing to the phenotype. A recent report described an association of a heterozygote insertion of six nucleotides in LHCGR with amenorrhea and poor oocyte recovery during IVF (66). In our patient, both ADAMTS19 and LHCGR mutations may have had additive pathogenic effects. Family segregation of mutant alleles would support such a hypothesis (Supplemental Fig. 1). Nevertheless, both mutations deserve functional tests to clarify their contribution to the phenotype.

POF23 was affected by the heterozygous LHCGRp.Ser176Pro mutation (Fig. 1). As this mutation was absent from our control populations and had computational predictions (protein alignments; SIFT, 0.03) compatible with a deleterious effect, this variant might contribute to patient phenotype (Table 2).

CONCLUSIONS

Taken together, our results lead to mutations in two novel genes (*ADAMTS19* and *BMPR2*) being potentially related to POF pathogenesis. We have also proposed that heterozygous *LHCGR* mutations might contribute, with variants in further POF candidate genes, to premature menopause. These assumptions must be validated by further sequencing projects and functional tests. We thus recommend NGS as a powerful tool for identifying new molecular actors in POF and for future diagnostic/prognostic purposes.

REFERENCES

- 1. Cox L, Liu JH. Primary ovarian insufficiency: an update. Int J Womens Health 2014;6:235–43.
- 2. Coulam CB. Premature gonadal failure. Fertil Steril 1982;38:645–55.

- Timmreck LS, Reindollar RH. Contemporary issues in primary amenorrhea. Obstet Gynecol Clin North Am 2003;30:287–302.
- Zinn AR, Ross JL. Turner syndrome and haploinsufficiency. Curr Opin Genet Dev 1998;8:322–7.
- Sherman SL. Premature ovarian failure in the fragile X syndrome. Am J Med Genet 2000;97:189–94.
- Laissue P, Vinci G, Veitia RA, Fellous M. Recent advances in the study of genes involved in non-syndromic premature ovarian failure. Mol Cell Endocrinol 2008;282:101–11.
- Aittomäki K, Lucena JL, Pakarinen P, Sistonen P, Tapanainen J, Gromoll J, et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 1995;82:959–68.
- Latronico AC, Anasti J, Arnhold IJ, Rapaport R, Mendonca BB, Bloise W, et al. Brief report: testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene. N Engl J Med 1996;334:507–12.
- Beau I, Touraine P, Meduri G, Gougeon A, Desroches A, Matuchansky C, et al. A novel phenotype related to partial loss of function mutations of the follicle stimulating hormone receptor. J Clin Invest 1998;102:1352–9.
- Touraine P, Beau I, Gougeon A, Meduri G, Desroches A, Pichard C, et al. New natural inactivating mutations of the follicle-stimulating hormone receptor: correlations between receptor function and phenotype. Mol Endocrinol 1999;13:1844–54.
- Rannikko A, Pakarinen P, Manna PR, Beau I, Misrahi M, Aittomäki K, et al. Functional characterization of the human FSH receptor with an inactivating Ala189Val mutation. Mol Hum Reprod 2002;8:311–7.
- Doherty E, Pakarinen P, Tiitinen A, Kiilavuori A, Huhtaniemi I, Forrest S, et al. A novel mutation in the FSH receptor inhibiting signal transduction and causing primary ovarian failure. J Clin Endocrinol Metab 2002;87:1151–5.
- Di Pasquale E, Beck-Peccoz P, Persani L. Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 (BMP15) gene. Am J Hum Genet 2004;75:106–11.
- Qin Y, Choi Y, Zhao H, Simpson JL, Chen Z-J, Rajkovic A. NOBOX homeobox mutation causes premature ovarian failure. Am J Hum Genet 2007;81:576–81.
- Zhao H, Chen Z-J, Qin Y, Shi Y, Wang S, Choi Y, et al. Transcription factor FIGLA is mutated in patients with premature ovarian failure. Am J Hum Genet 2008;82:1342–8.
- Lourenço D, Brauner R, Lin L, De Perdigo A, Weryha G, Muresan M, et al. Mutations in NR5A1 associated with ovarian insufficiency. N Engl J Med 2009;360:1200–10.
- Rossetti R, Di Pasquale E, Marozzi A, Bione S, Toniolo D, Grammatico P, et al. BMP15 mutations associated with primary ovarian insufficiency cause a defective production of bioactive protein. Hum Mutat 2009;30:804–10.
- Wu X, Wang B, Dong Z, Zhou S, Liu Z, Shi G, et al. A NANOS3 mutation linked to protein degradation causes premature ovarian insufficiency. Cell Death Dis 2013;4:e825.
- Caburet S, Arboleda VA, Llano E, Overbeek PA, Barbero JL, Oka K, et al. Mutant cohesin in premature ovarian failure. N Engl J Med 2014;370: 943–9.
- Santos MG, Machado AZ, Martins CN, Domenice S, Costa EM, Nishi MY, et al. Homozygous inactivating mutation in NANOS3 in two sisters with primary ovarian insufficiency. Biomed Res Int 2014;2014:787465.
- Hodges E, Xuan Z, Balija V, Kramer M, Molla MN, Smith SW, et al. Genomewide in situ exon capture for selective resequencing. Nat Genet 2007;39: 1522–7.
- Albert TJ, Molla MN, Muzny DM, Nazareth L, Wheeler D, Song X, et al. Direct selection of human genomic loci by microarray hybridization. Nat Methods 2007;4:903–5.
- Boycott KM, Vanstone MR, Bulman DE, MacKenzie AE. Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet 2013;14:681–91.
- Kiezun A, Garimella K, Do R, Stitziel NO, Neale BM, McLaren PJ, et al. Exome sequencing and the genetic basis of complex traits. Nat Genet 2012;44: 623–30.
- Koboldt DC, Steinberg KM, Larson DE, Wilson RK, Mardis ER. The nextgeneration sequencing revolution and its impact on genomics. Cell 2013; 155:27–38.

- Shyr D, Liu Q. Next generation sequencing in cancer research and clinical application. Biol Proced Online 2013;15:4.
- Lange LA, Hu Y, Zhang H, Xue C, Schmidt EM, Tang Z-Z, et al. Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. Am J Hum Genet 2014;94:233–45.
- Ortega-Recalde O, Vergara JI, Fonseca DJ, Ríos X, Mosquera H, Bermúdez OM, et al. Whole-exome sequencing enables rapid determination of xeroderma pigmentosum molecular etiology. PLoS One 2013;8:e64692.
- Patiño LC, Battu R, Ortega-Recalde O, Nallathambi J, Anandula VR, Renukaradhya U, et al. Exome sequencing is an efficient tool for variant late-infantile neuronal ceroid lipofuscinosis molecular diagnosis. PLoS One 2014;9:3–7.
- Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248–9.
- **31.** Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003;31:3812–4.
- 32. Santoro N. Update in hyper- and hypogonadotropic amenorrhea. J Clin Endocrinol Metab 2011;96:3281–8.
- Matzuk MM, Lamb DJ. Genetic dissection of mammalian fertility pathways. Nat Cell Biol 2002;4(Suppl):s41–9.
- Roy A, Matzuk MM. Deconstructing mammalian reproduction: using knockouts to define fertility pathways. Reproduction 2006;131:207–19.
- Matzuk MM, Lamb DJ. The biology of infertility: research advances and clinical challenges. Nat Med 2008;14:1197–213.
- Jagarlamudi K, Reddy P, Adhikari D, Liu K. Genetically modified mouse models for premature ovarian failure (POF). Mol Cell Endocrinol 2010; 315:1–10.
- Jagarlamudi K, Rajkovic A. Oogenesis: transcriptional regulators and mouse models. Mol Cell Endocrinol 2012;356:31–9.
- Cal S, Obaya AJ, Llamazares M, Garabaya C, Quesada V, López-Otín C. Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains. Gene 2002;283:49–62.
- Porter S, Clark IM, Kevorkian L, Edwards DR. The ADAMTS metalloproteinases. Biochem J 2005;386:15–27.
- Apte SS. A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (ADAMTS) superfamily: functions and mechanisms. J Biol Chem 2009;284:31493–7.
- Nicholson AC, Malik S-B, Logsdon JM, Van Meir EG. Functional evolution of ADAMTS genes: evidence from analyses of phylogeny and gene organization. BMC Evol Biol 2005;5:11.
- 42. Menke DB, Page DC. Sexually dimorphic gene expression in the developing mouse gonad. Gene Expr Patterns 2002;2:359–67.
- McClelland KS, Wainwright EN, Bowles J, Koopman P. Rapid screening of gene function by systemic delivery of morpholino oligonucleotides to live mouse embryos. PLoS One 2015;10:e0114932.
- 44. Bouma GJ, Hart GT, Washburn LL, Recknagel AK, Eicher EM. Using real time RT-PCR analysis to determine multiple gene expression patterns during XX and XY mouse fetal gonad development. Gene Expr Patterns 2004;5: 141–9.
- Lu P, Takai K, Weaver VM, Werb Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol 2011;3.
- 46. Knauff EA, Franke L, van Es MA, van den Berg LH, van der Schouw YT, Laven JS, et al. Genome-wide association study in premature ovarian failure patients suggests ADAMTS19 as a possible candidate gene. Hum Reprod 2009;24:2372–8.
- Pyun JA, Kim S, Cha DH, Kwack K. Epistasis between IGF2R and ADAMTS19 polymorphisms associates with premature ovarian failure. Hum Reprod 2013;28:3146–54.
- Pyun JA, Kim S, Kwack K. Epistasis between polymorphisms in ACVR2B and ADAMTS19 is associated with premature ovarian failure. Menopause 2015; 22:212–6.
- 49. Nohno T, Ishikawa T, Saito T, Hosokawa K, Noji S, Wolsing DH, et al. Identification of a human type II receptor for bone morphogenetic protein-4 that forms differential heteromeric complexes with bone morphogenetic protein type I receptors. J Biol Chem 1995;270:22522–6.

- Liu F, Ventura F, Doody J, Massagué J. Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol Cell Biol 1995;15:3479–86.
- Chang H, Brown CW, Matzuk MM. Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocr Rev 2002;23: 787–823.
- Shimasaki S, Moore RK, Otsuka F, Erickson GF. The bone morphogenetic protein system in mammalian reproduction. Endocr Rev 2004;25:72–101.
- 53. Massagué J, Seoane J, Wotton D. Smad transcription factors. Genes Dev 2005;19:2783–810.
- Moore RK, Otsuka F, Shimasaki S. Molecular basis of bone morphogenetic protein-15 signaling in granulosa cells. J Biol Chem 2003;278: 304–10.
- 55. Pulkki MM, Mottershead DG, Pasternack AH, Muggalla P, Ludlow H, van Dinther M, et al. A covalently dimerized recombinant human bone morphogenetic protein-15 variant identifies bone morphogenetic protein receptor type 1B as a key cell surface receptor on ovarian granulosa cells. Endocrinology 2012;153:1509–18.
- Peng J, Li Q, Wigglesworth K, Rangarajan A, Kattamuri C, Peterson RT, et al. Growth differentiation factor 9: bone morphogenetic protein 15 heterodimers are potent regulators of ovarian functions. Proc Natl Acad Sci U S A 2013;110:E776–85.
- Laissue P, Christin-Maitre S, Touraine P, Kuttenn F, Ritvos O, Aittomaki K, et al. Mutations and sequence variants in GDF9 and BMP15 in patients with premature ovarian failure. Eur J Endocrinol 2006;154:739–44.
- Machado RD, Rudarakanchana N, Atkinson C, Flanagan JA, Harrison R, Morrell NW, et al. Functional interaction between BMPR-II and Tctex-1, a

light chain of dynein, is isoform-specific and disrupted by mutations underlying primary pulmonary hypertension. Hum Mol Genet 2003;12:3277–86.

- 59. Foletta VC, Lim MA, Soosairaiah J, Kelly AP, Stanley EG, Shannon M, et al. Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1. J Cell Biol 2003;162:1089–98.
- Hassel S, Eichner A, Yakymovych M, Hellman U, Knaus P, Souchelnytskyi S. Proteins associated with type II bone morphogenetic protein receptor (BMPR-II) and identified by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2004;4:1346–58.
- Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA, Loyd JE, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000;26:81–4.
- Deng Z, Haghighi F, Helleby L, Vanterpool K, Horn EM, Barst RJ, et al. Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33. Am J Respir Crit Care Med 2000; 161:1055–9.
- Machado RD, Aldred MA, James V, Harrison RE, Patel B, Schwalbe EC, et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006;27:121–32.
- Li W, Dunmore BJ, Morrell NW. Bone morphogenetic protein type II receptor mutations causing protein misfolding in heritable pulmonary arterial hypertension. Proc Am Thorac Soc 2010;7:395–8.
- **65.** Ma L, Chung WK. The genetic basis of pulmonary arterial hypertension. Hum Genet 2014;133:471–9.
- Bentov Y, Kenigsberg S, Casper RF. A novel luteinizing hormone/chorionic gonadotropin receptor mutation associated with amenorrhea, low oocyte yield, and recurrent pregnancy loss. Fertil Steril 2012;97:1165–8.

SUPPLEMENTAL FIGURE 1



Pedigree of POF19 family. *Completely dashed symbols* refer to the affected individual (POF19) carrying both *BMPR2* and *LHCGR* mutations. *Half dashed symbols* refer to heterozygous carriers (*BMPR2* or *LHCGR* mutations).

SUPPLEMENTAL TABLE 1

Sequences used for multiple protein alignments.

Protein	Species	Protein sequence (GI)		
ADAMTS19	Homo sapiens Bos taurus Bison bison Pygoscelis adeliae Gallus gallus Xenopus tropicalis Pattur enprodicurs	112789555 194668875 742173366 690436459 513231250 512817668		
BMPR2	Mus musculus Mus musculus Homo sapiens Macaca mulatta Bos taurus Sus scrofa Gallus gallus Xenopus laevis Rattus norvegicus	28202057 15451916 383409919 296490468 325974528 47825379 147901570 281371326		
LHCGR	Homo sapiens Bos taurus Sus scrofa Gallus gallus Xenopus tropicalis Rattus norvegicus Mus musculus Danio Rerio	6080804 106067657 41386703 47523950 45384388 512844990 6981160 7305233 190336595		
Note: GI refers to the protein code from the NCBI database (http://www.ncbi.nlm.nih.gov/ protein/).				